neuMirRx Wins New US Patent for Drug Formulation Technology

neuMirRx, a specialty pharmaceutical company, has received a new US patent that covers novel formulation methods to enhance the solubility of hydrophobic compounds.

The rights to this patent and related proprietary technology, the neuNanoParticle, have been obtained by neuMirRx Corp through an exclusive license arrangement with Formatech of Andover, Massachusetts.

According to neuMirRx, it seeks to apply this patented technology to approved pharmaceutical products to develop and commercialize Qualiceuticals – the next generation pharmaceutical products with enhanced safety and efficacy profiles. neuMirRx also seeks to in-license or partner to extend the neuNanoParticle advantage to novel pharmaceutical compounds or new chemical entities.

Ben Isaacs, CEO of neuMirRx said: “The proprietary neuNanoParticle technology effectively solubilizes pharmaceutical compounds in micellar formulations containing fatty acids and fatty alcohols and further results in much higher maximum tolerated doses. In addition to addressing significant excipient related safety issues, the technology also delivers drug formulations that are compatible with parenteral (both liquid and lyophilized), oral, pulmonary and topical routes of administration.

“We are applying this novel technology to several commercially successful drugs in markets that welcome and support safer, more effective drug product formulation. This includes drugs such as Taxotere, Taxol, Diprivan and Cyclosporin.”

Mediware Expands Stock Buyback Plans

Mediware Information Systems, Inc. (NASDAQ: MEDW) announced today that the Company’s board of directors has authorized an expansion of its stock repurchase program. In February 2008 Mediware announced a plan to buy up to $4 million of the company’s common stock. To date, Mediware has repurchased 549,000 shares at a total cost of approximately $3.3 million.

The board of directors increased the funds available for stock repurchase by approximately $3.3 million. In total, the Company has been authorized to repurchase up to $7.3 million under the plan. The repurchases can be made at the discretion of the President and Chief Executive Officer or Chief Financial Officer of the Company. The Company has no obligation to repurchase shares under the program.

Commenting, Kelly Mann, Mediware’s chief executive officer said: “We continually monitor strategies such as acquisitions, new development and stock repurchases that leverage our strong cash position to the best interest of the business. The overall depression of the markets presents us the opportunity to expand our investment in support of our business and shareholders.”

About Mediware

Mediware delivers blood and medication management software systems that encapsulate information supporting patient therapies, reinforce patient safety practices and improve efficiencies to lower costs. Mediware’s customers include prestigious hospitals, clinics, correctional institutions, blood centers and other public and private health care institutions throughout the world. For more information about Mediware products and services, visit www.mediware.com.

Certain statements in this press release may constitute “forward-looking” statements within the meaning of the Private Securities Litigation Reform Act of 1995, as the same may be amended from time to time (the “Act”) and in releases made by the SEC from time to time. Such forward-looking statements are not based on historical facts and involve known and unknown risks, uncertainties and other factors disclosed in the Company’s Annual Report on Form 10-K for the year ended June 30, 2008, which may cause the actual results of the Company to be materially different from any future results expressed or implied by such forward-looking statements. The Company disclaims any obligation to update its forward-looking statements.

 Contact: Mark Williams 913.307.1000  

SOURCE: Mediware Information Systems

Pharos Innovations’ Remote Patient Monitoring Platform Screens and Identifies Depression Risk, Supports American Heart Recommendations

NORTHFIELD, Ill., Oct. 16 /PRNewswire/ — Pharos Innovations, a pioneer in assisting clients to achieve next generation clinical and financial performance improvement through a device-free remote monitoring platform, announced today a successful model for regular depression screening and follow-up via interactive voice response (IVR) and web-based technology. This model conforms to recommendations released last month by the American Heart Association (AHA).

(Logo: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH086LOGO)

“We were pleased but not surprised to see the AHA’s recommendations for regular depression screening for heart patients,” said Dr. Randall Williams, founder and CEO of Pharos. “Depression is not only more prevalent in those with complex chronic conditions, it also impedes treatment plan compliance and success. Depression screening, through the Patient Health Questionnaire (PHQ), is an integral part of the new paradigm of chronic care management that Pharos has developed with our Tel-Assurance(R) remote patient monitoring platform,” continued Dr. Williams.

According to a study, “Depression-Related Costs in Heart Failure Care,” published in the Archives of Internal Medicine, costs of care for heart failure patients with at least one hospitalization and evidence of depression are significantly higher than for heart failure patients without evidence of depression. The study suggests savings opportunities of up to $5 billion could be realized by effectively screening and treating heart failure patients for depression and other psychological distress.

Another study, “Telehealth Screen for Depression in a Chronic Illness Care Management Program,” published in Telemedicine and e-Health, presents data on Tel-Assurance as a model for using technology to manage co-morbid depression and chronic illness.

“Depression affects as many as half of individuals with heart failure, representing a significant co-morbid condition,” said Dr. Tom Kline, medical director of Iowa Medicaid Enterprise (IME). “Without the depression screening and follow-up as part of our Congestive Heart Failure Population Disease Management demonstration, we may not have seen the same breakthrough results that showed savings of $13,000 savings per member,” continued Kline.

In the IME demonstration, the Tel-Assurance depression screening identified 53% of participating patients as moderate to high risk of depression. Members at moderate risk were followed by the care coordinators. Members at high risk were referred to the mental health provider for additional follow up.

In the just released guidelines, The American Heart Association recommends that, because individuals with heart problems are three times more likely to become depressed, they should be screened regularly for signs of depression using the PHQ depression screener.

For a copy of the American Heart Association recommendation or for more information about Pharos Innovations, please contact Bonni Kaplan, senior director of marketing and communications for Pharos Innovations, at (847) 790-7649 or [email protected].

About Pharos Innovations

Founded in 1995, Pharos Innovations assists healthcare providers and payers in achieving next generation clinical and financial performance improvement. An innovative, device-free platform, Tel-Assurance(R), improves care coordination and drives dramatic clinical improvement and cost savings by remotely monitoring patients and averting unnecessary clinical events. Our enabling technologies proactively involve patients in their care and result in the early identification of clinical deterioration.

Tel-Assurance substantially expands the reach, efficiency and effectiveness of clients’ current health management programs for complex chronic conditions. The Pharos solution is strongly validated to show measured clinical improvement and financial impact, is the recipient of the prestigious American Heart Association National Outcomes award and was selected for the first ever National Institutes of Health (NIH) sponsored evaluation of remote monitoring interventions. For more information visit http://www.pharosinnovations.com/ or call (847) 790-7649.

    Contact:    Bonni L. Kaplan                Pharos Innovations                847-790-7649                [email protected]  

Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20080306/AQTH086LOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, [email protected]

Pharos Innovations

CONTACT: Bonni L. Kaplan of Pharos Innovations, +1-847-790-7649,[email protected]

Web site: http://www.pharosinnovations.com/

Obagi Medical Products’ ELASTIderm Decolletage System Reduces Visible Signs of Aging on Chest and Neck

Obagi Medical Products, Inc. (Nasdaq:OMPI), a leader in topical aesthetic and therapeutic skin health systems, today announced positive study results at the Fall Clinical Dermatology Conference Meeting showing that use of its ELASTIderm(TM) Decolletage System is highly effective in improving photodamaged skin of the chest and neck, also known as decolletage. The skin care system showed significant improvements in as early as 2 weeks. The treatment was also well tolerated and provided patients with high levels of satisfaction.

“In recent years, it has become clear to me that many women are doing a much better job of protecting their faces from sun damage; however, they continue to neglect their neck and chest area. It is common to see a woman with mild photodamage of their face and a heavily pigmented, rough and wrinkled chest. The results of this study speak for themselves. The system is highly effective, with the most obvious improvements in mottled hyperpigmentation occurring early in treatment, which continued to improve over time, as did wrinkling,” said James Leyden, MD, Emeritus Professor, University of Pennsylvania Health Systems and KGL, Inc., and lead investigator.

ELASTIderm(TM) Decolletage System is the only topical system backed by data from a 24-week clinical study that is designed to treat hyperpigmentation, including age spots and freckles, while reducing the appearance of fine lines and wrinkles. The System works by helping to replenish elasticity and build collagen in the chest and neck area. It is based on the Company’s patented Penetrating Therapeutics(TM) technology that allows for greater penetration across the skin barrier to help stimulate elasticity and increase the overall resiliency of the skin.

“Skin around the neck and chest is often overlooked in the anti-aging treatment process and our system can assist skin care professionals in providing the total rejuvenating results their patients want,” said Steve Carlson, President and Chief Executive Officer of Obagi Medical Products. “We are proud that the ELASTIderm Decolletage System technology can provide patients such significant improvement in the reduction of fine lines and wrinkles, as well as effectively treating hyperpigmentation.”

Study Methodology

Study subjects had a decolletage area with at least moderate levels of photodamage and at least moderate levels of mottled hyperpigmentation, fine wrinkling, or coarse wrinkling. All subjects applied the ELASTIderm(TM) Decolletage System to their entire decolletage twice daily for 24 weeks.

Baseline assessments of the Investigator’s Overall Integrated Assessment of Photodamage, the primary endpoint of the study, showed that all patients had very severe to moderate photodamage at the start of the study. By week 12, 53% of patients had only minimal to mild photodamage, increasing to 69% at week 24.

At the start of the study, all patients had moderate to severe levels of hyperpigmentation associated with sun damage. By week 24, 79% of patients had minimal to no signs of hyperpigmentation.

In addition, prior to treatment, all patients had moderate to severe levels of fine wrinkling. By week 24, 100% of patients had only mild to minimal levels of fine wrinkling.

Overall, 95% of patients were “satisfied” or “very satisfied” with the overall improvement of their decolletage at week 24.

About the ELASTIderm(TM) Decolletage System

The ELASTIderm(TM) Decolletage System is a physician-dispensed skincare system that consists of two clinically proven topical skin treatments — ELASTIderm Skin Lightening Complex and ELASTIderm Wrinkle Reducing Lotion. The ELASTIderm Skin Lightening Complex is formulated with 4% hydroquinone to aid in the gradual lightening of hyperpigmented skin conditions. The ELASTIderm Wrinkle Reducing Lotion is formulated with a proprietary bi-mineral complex with malonic acid that helps replenish elasticity and build collagen.

About Obagi Medical Products, Inc.

Obagi Medical Products develops and commercializes skin health products for the dermatology, plastic surgery, and related aesthetic markets. Using its Penetrating Therapeutics(TM) technologies, Obagi Medical’s products are designed to improve penetration of agents across the skin barrier for common and visible skin conditions in adult skin including chloasma, melasma, senile lentigines, acne vulgaris and sun damage. The history of Obagi’s skin care product introductions is as follows: Obagi Nu-Derm(R), 1988; Obagi-C(R) Rx (the first and only prescription-strength vitamin C and hydroquinone system), 2004; Obagi(R) Professional-C (a line of highly stable vitamin C serums), 2005; Obagi(R) Condition and Enhance for use with cosmetic procedures to enhance patient outcomes and satisfaction, 2006; Obagi ELASTIderm(TM) eye treatment and Obagi CLENZIderm(R) M.D. acne therapeutic systems, 2007; a formulation of Obagi CLENZIderm(R) M.D. Systems for normal to dry skin, June 2007; and Obagi ELASTIderm(TM) Decolletage System, January 2008 and SoluCLENZ Rx Gel for the pharmacy channel in August 2008. Visit www.obagi.com for information.

Forward Looking Statements

There are forward-looking statements contained herein, which can be identified by the use of forward-looking terminology such as the words “believes,””expects,””may,””will,””should,””potential,””anticipates,””plans,” or “intends” and similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results, events or developments to be materially different from the future results, events or developments indicated in such forward-looking statements. Such factors include, but are not limited to the intense competition our products face and will face in the future, the level of market acceptance of our products, the possibility that our products could be rendered obsolete by technological or medical advances, the possibility that we may become involved in intellectual property claims and litigation that could adversely affect the profitability of or our ability to sell our products, the possibility that our products may cause undesirable side effects and the fact that our ability to commercially distribute our products may be significantly harmed if the regulatory environment governing our products changes. A more detailed discussion of these and other factors that could affect results is contained in our filings with the U.S. Securities and Exchange Commission, including our Form 10-K for the year ended December 31, 2007. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. No assurance can be given that the future results covered by the forward-looking statements will be achieved. All information in this press release is as of the date of this press release and Obagi Medical Products does not intend to update this information.

Children’s Virtual World Wins Real World W3 Award

OAKLAND, Calif., Oct. 16 /PRNewswire/ — The 3rd Annual W3 Awards has given Handipoints.com the gold for Best Family/Parenting Website of 2008. Handipoints is a site where parents can create printable chore charts and set up an allowance program that teaches kids responsible habits. Kids earn points for doing their chores, homework, and staying healthy. They use their points to buy rewards from their parents or to play games, watch cartoons, and adopt and accessorize a cartoon Cool Cat. All the fun happens in HandiLand, a safe and exciting world where kids meet and play with friends. Handipoints.com is an exciting combination of entertainment and productivity for families online.

Now the dynamic virtual world and rich chore chart features at Handipoints.com have earned one of the Web’s highest honors. The W3 Awards are famous for honoring excellence on the Internet and “Recognizing the Power of Web Creativity.”

“We are thrilled to join the list of fellow W3 winners,” says Handipoints founder and CEO Viva Chu. “Our focus on kids staying healthy and active in the real world is truly unique and it feels great to be recognized for this innovative thinking.”

The 3rd Annual W3 Awards received over 3,000 entries from all over the world. As one of only two winners in the Family/Parenting Website category, Handipoints.com is truly among the best family Web sites online today. Recent issues of Real Simple and Parenting Magazine have listed Handipoints as a must-visit Web site for parents and kids alike. Parents can sign up for free and try it out today at http://www.handipoints.com/.

About Handipoints:

A privately owned company based in Oakland, Calif., Handipoints is a virtual community for families where children’s “real world” chores earn big prizes and new adventures in a safe, fun and educational online environment. Unlike other children’s Web sites, Handipoints marries offline tasks with online games and entertainment to teach children the value of their work and foster good behavior. While they’re having fun online, children learn about saving and building responsible habits in their daily lives. More information can be found at http://www.handipoints.com/.

   Contact:    Mary Kolesnikova, Community Outreach Director   (650) 520-5287   [email protected]    

This release was issued through eReleases(TM). For more information, visit http://www.ereleases.com/.

Handipoints.com

CONTACT: Mary Kolesnikova, Community Outreach Director ofHandipoints.com, +1-650-520-5287, [email protected]

Web site: http://www.handipoints.com/

AT&T Global Services Canada Supports the International Women’s Forum

TORONTO, Oct. 16 /PRNewswire-FirstCall/ — AT&T Inc. today announced a contribution of $12,500 to the International Women’s Forum of Canada (IWFC). The donation will provide a scholarship for a woman in the non-profit sector in Canada to participate in the IWF Leadership Foundation Fellows Program. The Fellows Program is the premier international leadership and executive development program for emerging women leaders around the world.

Each year, the IWF Leadership Foundation selects approximately 30 talented women from academia, corporations, government and the non-profit sector to participate in the development program. Produced in partnership with the Harvard Business School and the Judge Business School, Cambridge University, the Fellows program is coveted by women aspiring to be in the most senior leadership positions. The purpose of this Fellows Program is to apply members’ expertise and experience to benefit women around the globe.

“AT&T Global Services Canada places extremely high value on the experience and expertise women bring to our day-to-day operations. We have a significant number of women in leadership positions throughout our organization,” stated Mary Livingston, AT&T Global Services Vice President for Canada, Caribbean and Latin America.

“We are very pleased to support the IWF because we fundamentally believe that the opportunities provided by participation in the IWF Fellows Program are both important for the continued advancement of professional women and an invaluable experience for the female leaders of tomorrow.”

The Fellows Program does not end in the classroom. Opportunities are created for fellows to share their experience and alumnae continue to learn from the best, promoting the evolution of a mentorship culture for women.

“IWF Canada is thrilled to be the recipient of this contribution,” stated Alison Youngman, President of IWF Canada and a member of the Board of the IWF global Leadership Foundation. “Corporate Canada has participated in the IWF Leadership Foundation Program for many years but this grant, together with matching funds from IWF Canada, will enable us to support a Fellow who might otherwise never have access to this amazing program.”

The IWF is a global membership association of preeminent female business executives, heads of state, government, and leaders in the arts, sciences, diplomacy and more. Internationally, more than 4,400 women participate in the IWF in 22 nations. Founded in 1982, IWF Canada is a leading affiliate within the organization. The IWFC has chapters in Calgary, Toronto, Waterloo region, Ottawa, Montreal and Halifax. The Leadership Foundation is the non-profit educational arm of IWF.

About Philanthropy at AT&T

AT&T Inc. is committed to advancing education, strengthening communities and improving lives. Through its philanthropic initiatives and partnerships, AT&T supports projects that create learning opportunities; promote academic and economic achievement; and address community needs. In 2007, AT&T contributed more than $164 million through corporate-, employee- and AT&T Foundation-giving programs. AT&T and the AT&T Foundation, the corporate philanthropy organization of AT&T, combine more than $1.9 billion of historic charitable commitment to communities across the country.

About AT&T

AT&T Inc. is a premier communications holding company. Its subsidiaries and affiliates, AT&T operating companies, are the providers of AT&T services in the United States and around the world. Among their offerings are the world’s most advanced IP-based business communications services and the nation’s leading wireless, high speed Internet access and voice services. In domestic markets, AT&T is known for the directory publishing and advertising sales leadership of its Yellow Pages and YELLOWPAGES.COM organizations, and the AT&T brand is licensed to innovators in such fields as communications equipment. As part of its three-screen integration strategy, AT&T is expanding its TV entertainment offerings. In 2008, AT&T again ranked No. 1 on Fortune magazine’s World’s Most Admired Telecommunications Company list and No. 1 on America’s Most Admired Telecommunications Company list. Additional information about AT&T Inc. and the products and services provided by AT&T subsidiaries and affiliates is available at http://www.att.com/.

(C) 2008 AT&T Intellectual Property. All rights reserved. AT&T, the AT&T logo and all other marks contained herein are trademarks of AT&T Intellectual Property and/or AT&T affiliated companies.

Note: This AT&T news release and other announcements are available as part of an RSS feed at http://www.att.com/rss. For more information, please review this announcement in the AT&T newsroom at http://www.att.com/newsroom.

AT&T Inc.

CONTACT: Joanne Kearney, +1-416-645-8180, [email protected],for AT&T Inc.

Web site: http://www.att.com/

HealthCare.Com Acquires BrokersWeb.Com, the Leading Health Insurance Pay-Per-Click Marketing Platform

MIAMI, Oct. 16 /PRNewswire/ — HealthCare.com, Inc. (http://www.healthcare.com/) today announced the acquisition of BrokersWeb (http://www.brokersweb.com/), a leading provider of targeted, performance-based online advertising to health insurance brokers and lead aggregators. In addition to operating the BrokersWeb health insurance pay-per-click (PPC) platform, BrokersWeb also owns and operates HealthInsuranceFinders.com (http://www.healthinsurancefinders.com/), a leading consumer health insurance website and search engine for health insurance quotes.

Headquartered in Redlands, CA, BrokersWeb provides its more than 250 advertisers the most-targeted source of PPC advertising generated from consumer health insurance queries. BrokersWeb’s proprietary technology allows its advertisers to bid for placement to their paid listings and pay on a per-click basis. In addition, BrokersWeb provides advertisers with additional online conversion tools such as a ROI analytics, bid transparency and branded lead generation micro-sites.

The main distribution outlet for BrokersWeb’s sponsored search results is its consumer portal HealthInsuranceFinders.com, a leading health insurance information resource and quote search engine. Launched in 2001, HealthInsuranceFinders.com provides consumers with information about purchasing and understanding the complexities of health insurance, along with a search tool to find health insurance quotes from multiple brokers and agents.

Todd Faucher, founder and President of BrokersWeb will continue to lead the business on a day-to-day basis. The addition of BrokersWeb extends the growth of HealthCare.com, a leader in health care provider information, into the health insurance area. BrokersWeb will become an operating division of HealthCare.com, and will anchor HealthCare.com’s Health Insurance Search business.

“The acquisition of BrokersWeb strengthens our presence and fits within HealthCare.com’s mission to help consumers make better health care decisions,” said Matias de Tezanos, founder and CEO of HealthCare.com. “From a business standpoint, the acquisition brings together a leading media property and a proprietary monetization platform that HealthCare.com will be able to expand. We are excited to welcome the BrokersWeb team.”

“Our combination with HealthCare.com brings substantial momentum and the right resources to grow our business,” said Todd Faucher, President of BrokersWeb. “Our client base will benefit from HealthCare.com’s reach and financial strength, and we look forward to becoming part of the HealthCare.com team.”

About HealthCare.com, Inc.

HealthCare.com, with its flagship web property at http://www.healthcare.com/, features Care Provider Search(TM), the web’s leading healthcare provider directory connecting health consumers with health care professionals and health care-related businesses. In addition to operating a leading online health website, HealthCare.com has syndicated Care Provider Search(TM) to leading newspaper websites, local media and health portals, allowing its partners’ audiences to engage with local health providers. Syndication partners include The McClatchy Company (Miami Herald and The Olympian), MedHelp, AOL Health, Everyday Health, dLife, drugstore.com. In addition, HealthCare.com offers health content and information through a health portal, health content search, medication search, and health insurance search. For additional information, please visit http://www.healthcare.com/.

   Contact:   Jose Vargas   HealthCare.com, Inc.   Phone: (786) 472-2966   Email: [email protected]  

HealthCare.com, Inc.

CONTACT: Jose Vargas of HealthCare.com, Inc., +1-786-472-2966,[email protected]

Web site: http://www.healthcare.com/http://www.brokersweb.com/http://www.healthinsurancefinders.com/

Epigenomics AG Reports Successful Completion and Positive Results From Prostate Cancer Clinical Study

BERLIN and SEATTLE, Oct. 16, 2008 (GLOBE NEWSWIRE) — Epigenomics AG (Frankfurt:ECX) (Prime Standard), a cancer molecular diagnostics company developing tests based on DNA methylation, today reported positive final results from its prognostic prostate cancer study.

“After testing all patient samples for methylation in the PITX2 gene we have successfully conducted our final analysis,” commented Dr. Gunter Weiss, Vice President Product Development at Epigenomics. “This analysis shows that PITX2 gene methylation is indeed a strong, independent prognostic marker that can help guide physicians to determine a patient’s risk for relapse. The analysis demonstrated statistical significance for all study endpoints,” Dr. Weiss added.

The clinical study successfully analyzed paraffin embedded tissue samples from 476 prostate cancer patients collected at four major clinical centers in Europe and the USA who had undergone radical prostatectomy, with the objective of validating the prognostic utility of Epigenomics’ proprietary biomarker, PITX2. The primary endpoint of the study was to evaluate the methylation status of the PITX2 gene as an independent prognostic biomarker indicative of the risk of prostate cancer biochemical recurrence in patients following removal of the entire prostate, known as radical prostatectomy. This primary endpoint of the study was met by the statistically significant demonstration that patients with elevated PITX2 gene methylation level had a threefold higher risk of relapse following prostatectomy compared to patients with low PITX2 methylation (hazard ratio 3.0; p less than 0.00005).

As secondary endpoints, the study also analyzed whether measurement of PITX2 methylation adds clinical information to established prognostic parameters such as age, Gleason Score, tumor staging, pre-surgical PSA levels and surgical margin status. In each of the pair wise comparisons of PITX2 with one of these established parameters, high PITX2 gene methylation was an independent prognostic factor indicating more than double the risk compared to patients with low PITX2 gene methylation (hazard ratios greater than 2.3; p less than 0.0001). In the group of patients with an intermediate Gleason Score of 7, which present difficult decisions for doctors and patients due to difficulty in determining their prognosis, the PITX2 marker was able to discriminate patients into those with a high and low risk of disease recurrence (hazard ratio 2.0; p=0.005). PITX2 gene methylation remained a statistically significant independent prognostic factor even when it was combined with several established parameters (hazard ratio 1.9; p=0.004) demonstrating its added value in guiding patient management.

The study confirmed the clinical utility of the PITX2 biomarker for prostate cancer prognosis, first established in a 2006 clinical study on 605 prostatectomy tissue samples using real time PCR. In the current study the PITX2 gene methylation was measured reliably using an Affymetrix GeneChip(TM) platform, confirming the robustness of the marker across various assay technologies suitable for routine laboratory use.

Epigenomics has designed and analyzed the study together with its clinical collaborators at Baylor College of Medicine, Houston, Texas, USA, at Erasmus Medical Center, Rotterdam, The Netherlands, at Duke University Medical Center and the VA Medical Center at Durham, North Carolina, USA, and University Hospital Erlangen, Erlangen, Germany. A Publication of the clinical study data is planned in a peer-reviewed journal in due course.

“This test has appeared to add valuable prognostic information in every patient group in which it has been used,” commented Stephen J. Freedland, MD, Staff Physician at the Durham VA and Associate Professor of Urology and Pathology in the Duke Prostate Center, Duke University Medical Center. “As an in vitro diagnostic test, this could be another important tool for patients who are seeking additional prognostic information beyond what is currently available,” he continued.

“The prognostic information provided for patients at intermediate or high risk is especially remarkable,” emphasized Prof. Thomas Wheeler, MD, Chair of the Department of Pathology at the Baylor College of Medicine. “Especially, this large group of patients should profit from the results of the tests.”

“These are very good results based on rigorous study design and high quality data,” explained Prof. Dr. Chris Bangma, Chairman of the Department of Urology at the ERASMUS Medical Center. “The reliability of the PCMCT assay is very remarkable and provides the basis for routine laboratory use,” he added. This notion was confirmed by Prof. Dr. Arndt Hartmann, Director of the Institute of Pathology at the University Hospital in Erlangen who stated: “Technically, this has been a perfect study. For all but a single patient a valid PITX2 measurement has been provided. The technology is mature and ready for release.”

Following these highly successful results of its clinical study Epigenomics intends to make the PITX2 assay available to clinicians and patients as soon as possible and is exploring several opportunities to commercialize PITX2. The marker has additional potential applications beyond prostate cancer prognosis, such as in breast cancer. Commercial options include licensing the biomarker and a suitable assay technology to reference laboratories, the launch of RUO products for clinical research in Europe, and potentially the transfer of the fully developed assay system to suitable partners for regulatory submission and commercialization as an IVD product. About Epigenomics’ Prostate Cancer Molecular Classification Test

Prostate cancer is the most common cancer in American and European men. With an annual incidence of approximately 470,000 cases in the US and Europe, one in six men will be diagnosed with prostate cancer in his lifetime and about 100,000 men will die from the disease every year. Surgical removal of the prostate (radical prostatectomy) is performed as potentially curative treatment in about 40% of patients diagnosed with prostate cancer. Nevertheless, the disease recurs in about one in seven prostatectomy patients. However, the difficulty clinicians have is that even with the use of current prognostic parameters, there still remains considerable uncertainty concerning which patients will eventually relapse. Epigenomics is developing a prostate cancer molecular classification test based on the DNA methylation biomarker PITX2 that will provide physicians and patients with prognostic information on disease recurrence by identifying those prostatectomy patients at increased risk. Currently, prognostic information is mainly derived from clinical and histopathological parameters, such as tumor size, Gleason Score and pre-surgery PSA levels. In a study published at the 2006 annual AACR meeting, Epigenomics has shown that DNA methylation of PITX2 constitutes a strong prognostic marker for outcome prediction after radical prostatectomy. In this study, PITX2 separated post-prostatectomy cancer patients into two distinct groups: Those with a high likelihood of cancer recurrence and those with a low likelihood of cancer recurrence. Furthermore, PITX2 methylation added significant information to established clinical parameters. Remarkably, the PITX2 biomarker was able to predict outcome in patients diagnosed with Gleason 7, for which reliable prognosis based on conventional parameters is particularly difficult. These findings were now confirmed with the study published today. The demand among physicians for such a molecular diagnostic test is high, since it identifies patients with a poor prognosis that are possibly under-treated.

About Epigenomics AG

Epigenomics is a molecular diagnostics company with a focus on the development of novel products for cancer. Using DNA methylation biomarkers, Epigenomics’ tests in development aim at diagnosing cancer at an early stage before symptoms occur and thereby may reduce mortality from this dreaded disease.

Epigenomics’ product pipeline contains a validated biomarker for the early detection of colorectal cancer in blood plasma, and further proprietary DNA methylation biomarkers at various stages of development for prostate and lung cancer detection in urine, blood and bronchial lavage specimens. Epigenomics’ biomarker Septin 9 for the early detection of colorectal cancer in a simple blood sample demonstrated continuously highest performance in multiple clinical studies with in total more than 3,500 individuals tested.

For development and global commercialization as in vitro diagnostic test kits, Epigenomics pursues a non-exclusive partnering strategy with diagnostics industry companies. As a first strategic partner, Abbott Molecular Inc. licensed the worldwide non-exclusive IVD rights to Epigenomics’ proprietary Septin 9 biomarker for colorectal cancer. Epigenomics also aims at giving patients and doctors early access to these biomarkers through reference laboratory testing services. As a first reference laboratory partner, Quest Diagnostics Inc., the leading provider of diagnostic testing, information and services, obtained the license to commercialize a laboratory-developed test (LDT) for Septin 9 in the U.S.

Partners in the health care industry and the biomedical research community can access Epigenomics’ portfolio of proprietary DNA methylation technologies and biomarkers protected by more than 150 patent families through research products, Biomarker Services, IVD Development Collaborations, and Licensing. The company is headquartered in Berlin, Germany, and has a wholly owned subsidiary in Seattle, WA, U.S.A. For more information, please visit Epigenomics’ website at www.epigenomics.com.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning Epigenomics AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors which could cause the actual results, financial condition, performance or achievements of Epigenomics AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Epigenomics AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

This news release was distributed by GlobeNewswire, www.globenewswire.com

 CONTACT: Epigenomics AG          Dr. Achim Plum, SVP Corporate Development          +49 30 24 345 368          [email protected] 

BioMarin Announces Positive Results From Phase 2A Clinical Study of 6R-BH4 in Sickle Cell Disease

NOVATO, Calif., Oct. 15 /PRNewswire-FirstCall/ — BioMarin Pharmaceutical Inc. today announced results from its Phase 2a multi-center, open-label, dose-escalation clinical study of 6R-BH4 in patients with sickle cell disease (SCD) designed to evaluate whether 6R-BH4 can improve the endothelial dysfunction observed in SCD patients. Oral administration of 6R-BH4 was associated with an improvement in endothelial dysfunction in sickle cell disease patients.

   Key findings from the study:    -- Endothelial dysfunction, measured using the EndoPAT device to assess      peripheral arterial tonometry (PAT), was common in the sickle cell      disease patient population.  At baseline, 56% of the patients in the      trial had endothelial dysfunction (PAT score less than or equal to      1.67), consistent with prior studies using other methods for measuring      endothelial function.   -- Endothelial dysfunction in SCD patients treated with escalating doses      of 6R-BH4 showed improvement at week 8 (5 mg/kg; p=0.042), week 12      (10mg/kg; p=0.003) and week 16 (20 mg/kg; p=0.075).   -- SCD patients with an abnormal PAT scores of less than or equal to      1.67 at baseline demonstrated greater improvement at all dose      levels (2.5, 5, 10 and 20 mg/kg).   -- The mean endothelial function PAT score improved from the abnormal to      the normal range (>1.67) in SCD patients with an abnormal PAT score at      baseline.   -- Improvement in endothelial dysfunction appeared to be dose-dependent.   -- 6R-BH4 was well-tolerated in sickle cell disease patients.    

Pending feedback from the FDA at a pre-IND meeting in November, future development plans could include a cross-sectional study in sickle cell disease patients to assess the relationship between endothelial dysfunction and the frequency and severity of sickle cell crises, and a three month double-blind, placebo-controlled dose finding study with a primary endpoint of improvement in endothelial function.

Emil Kakkis, M.D., Ph.D., Chief Medical Officer of BioMarin stated, “We are very encouraged by the study results as it suggests that the known severe endothelial dysfunction present in sickle cell disease patients is due to an acquired BH4 deficiency and is responsive to 6R-BH4 replacement therapy. Endothelial dysfunction in SCD is now believed to play a greater role in the pathophysiology of sickle cell vasoocclusive crises than had previously been realized. The ability to reverse this dysfunction with oral 6R-BH4 therapy represents a new opportunity to treat SCD.”

Dr. Kakkis continued, “The EndoPAT device is a new reproducible method to measure the effect of endothelial dysfunction on small vessel function and has been adopted by the ongoing Framingham study of cardiovascular risks and outcomes as recently published. The PAT score has been shown to correlate with other cardiovascular risk factors and endothelial dysfunction in general has been shown to predict adverse cardiovascular events in at least 10 prospective studies. With this current SCD study, we have an indication that 6R-BH4 is active in improving endothelial function, and we hope to establish a clear relationship between the degree of endothelial dysfunction and the frequency and severity of sickle cell crises using a survey of SCD patients with the EndoPAT test.”

“Sickle cell disease is a chronic, lifelong disease that affects a significantly large population of approximately 100,000 people in the U.S. These patients suffer periods of intense pain, poor blood flow, organ damage and other serious medical complications. To date, however, there are very limited treatment options for this debilitating disease and average life expectancy is only in the forties,” said Lewis Hsu, M.D., Ph.D., Associate Professor of Pediatric Hematology & Interim Director of Marian Anderson Comprehensive Sickle Cell Center, St. Christopher’s Hospital for Children, Drexel University College of Medicine, Philadelphia, PA. “These study findings are significant and support the concept of using BH4 to treat sickle cell disease, a somewhat novel but plausible approach. Recent reviews of the pathophysiology in sickle cell disease have shifted the focus away from the physical sickling of red blood cells and more toward the deteriorating health of the blood vessels resulting from hemolysis and the release of hemoglobin from red cells.”

Study Design

The Phase 2a multi-center, open-label study enrolled 32 subjects and was conducted at 12 U.S. sites. Among other eligibility criteria, to participate in the study, SCD patients were at least 15 years of age and were not receiving hydroxyurea or hypertransfusion therapy. Study patients received 6R-BH4 at 2.5 mg/kg, 5 mg/kg, 10 mg/kg and 20 mg/kg for four weeks each in a 16-week dose-escalation study. A total of 21 patients completed the baseline and final assessments.

The primary objective in the study was to evaluate the safety of oral 6R-BH4 administered in escalating doses in patients with sickle cell disease. The secondary objective was to evaluate changes in physiological and biochemical markers of endothelial function which underlie some key aspects of SCD. PAT scores were measured at the end of each 4 week dose period and compared to the baseline PAT score for statistical purposes.

Abstract at American Society of Hematology Conference

Abstract: Peripheral Arterial Tonometry Assessment of Endothelial Dysfunction in Sickle Cell Patients

   First Author: Lewis Hsu, M.D., Ph.D.   Date: December 7, 2008   Poster Presentation Time: 6:00 p.m.-8:00 p.m.     Conference Call Information  

BioMarin will hold a conference call today, October 15, 2008, at 5:00 p.m. ET to discuss the results of the Phase 2a study of 6R-BH4 in sickle cell disease. This event can be accessed on the investor section of the BioMarin website at http://www.bmrn.com/.

   Date: October 15, 2008   Time: 5:00 p.m. ET   U.S. and Canada Toll-Free Dial in #: 866.356.4123   International Dial in #: 617.597.5393   Participant Code: 75782382   Replay Toll-Free Dial in #: 888.286.8010   Replay International Dial in #: 617.801.6888   Replay Code: 73130467     About 6R-BH4  

6R-BH4, commonly known as BH4 or tetrahydrobiopterin, is a naturally occurring enzyme cofactor that is required for numerous biochemical and physiologic processes, including the synthesis of nitric oxide (NO). NO has been shown to play a key protective role throughout the cardiovascular system and produces multiple positive effects, such as relaxing smooth muscle, reducing blood pressure, controlling inflammation and reducing platelet aggregation. Researchers have demonstrated that a deficiency of BH4 can disrupt NO synthesis, resulting in a loss of normal endothelial NO production. This loss of endothelial NO production, commonly referred to as endothelial dysfunction, has been associated with many cardiovascular diseases, including hypertension, diabetic vascular disease, peripheral arterial disease, coronary arterial disease and pulmonary hypertension, and has been shown to be a strong predictor of cardiovascular adverse events in a number of clinical studies.

About BioMarin

BioMarin develops and commercializes innovative biopharmaceuticals for serious diseases and medical conditions. The company’s product portfolio comprises three approved products and multiple clinical and pre-clinical product candidates. Approved products include Naglazyme(R) (galsulfase) for mucopolysaccharidosis VI (MPS VI), a product wholly developed and commercialized by BioMarin; Aldurazyme(R) (laronidase) for mucopolysaccharidosis I (MPS I), a product which BioMarin developed through a 50/50 joint venture with Genzyme Corporation; and Kuvan(R) (sapropterin dihydrochloride) Tablets, a product for the treatment of phenylketonuria (PKU), developed in partnership with Merck Serono, a division of Merck KGaA of Darmstadt, Germany. Other product candidates include 6R-BH4 for cardiovascular indications, which is currently in Phase 2 clinical development for the treatment of peripheral arterial disease and sickle cell disease, and PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase), which is currently in Phase 1 clinical development for the treatment of PKU. For additional information, please visit http://www.bmrn.com/. Information on BioMarin’s website is not incorporated by reference into this press release.

Forward-Looking Statement

This press release contains forward-looking statements about the business prospects of BioMarin Pharmaceutical Inc., including, without limitation, statements about: expectations related to BioMarin’s clinical trials of 6R-BH4 for sickle cell disease and other indications, actions by regulatory authorities and the general development of BH4 for sickle cell. These forward-looking statements are predictions and involve risks and uncertainties such that actual results may differ materially from these statements. These risks and uncertainties include, among others: results and timing of current and planned preclinical studies and clinical trials; the ability to enroll patients in future trials in a timely manner; the actual correlation between PAT scores and clinical endpoints; the content and timing of decisions by the U.S. Food and Drug Administration, the European Commission and other regulatory authorities concerning each of the described products and product candidates; the market for each of these products; and those factors detailed in BioMarin’s filings with the Securities and Exchange Commission, including, without limitation, the factors contained under the caption “Risk Factors” in BioMarin’s 2007 Annual Report on Form 10-K, and the factors contained in BioMarin’s reports on Form 10-Q. Stockholders are urged not to place undue reliance on forward-looking statements, which speak only as of the date hereof. BioMarin is under no obligation, and expressly disclaims any obligation to update or alter any forward-looking statement, whether as a result of new information, future events or otherwise.

BioMarin(R) , Naglazyme(R) and Kuvan(R) are a registered trademarks of BioMarin Pharmaceutical Inc.

   Aldurazyme(R) is a registered trademark of BioMarin/Genzyme LLC.     Contact:    Investors                                    Media    Eugenia Shen                                 Susan Berg    BioMarin Pharmaceutical Inc.                 BioMarin Pharmaceutical Inc.    (415) 506-6570                               (415) 506-6594  

BioMarin Pharmaceutical Inc.

CONTACT: Investors, Eugenia Shen, +1-415-506-6570, or Media, Susan Berg,+1-415-506-6594, both of BioMarin Pharmaceutical Inc.

Web site: http://www.bmrn.com/

Volcano Corporation Announces Launch of PrimeWire(TM) Pressure Guidewire and S5-FFR Option for Existing Fleet of S5 IVUS Consoles

WASHINGTON, Oct. 15 /PRNewswire-FirstCall/ — Volcano Corporation today announced the launch of the PrimeWire(TM) Pressure Guidewire, and the s5-FFR Option for its existing installed base of s5 and s5i imaging consoles in the U.S. The PrimeWire is Volcano’s newest pressure guidewire, capable of measuring pressure gradients across a lesion to determine the ischemic nature of the stenosis, and can also help determine the extent to which the blockage is flow-limiting. The s5-FFR Option is now available for existing s5 and s5i consoles currently installed throughout the U.S. and Europe to enable these IVUS consoles with FFR (fractional flow reserve) technology. Volcano continues to be the only company offering an imaging console capable of high-frequency rotational IVUS, fast digital IVUS, and FFR.

FAME

The one-year follow-up of the FAME study (FFR vs. Angiography for Multivessel Evaluation) was presented yesterday at TCT and confirms the beneficial clinical and economic impact of FFR when used routinely to guide treatments of multi-vessel disease. “The FAME study is among the most important studies in today’s DES therapy era. FAME demonstrates that when physicians employ FFR to guide multi-vessel PCI treatment, their patients benefit both clinically and economically. The FFR-guided interventions for multi-vessel disease are also cost effective for hospitals and payers. FAME confirms the benefits of routine FFR for the multi-vessel patient just as the earlier Deferral versus Performance of PTCA in Patients Without Documented ischemia (DEFER) study demonstrated in single-vessel disease, but does so in a larger patient population and in a randomized fashion,” commented Morton Kern, MD, professor of medicine and associate chief, Division of Cardiology, University of California, Irvine.

FAME randomized 1005 patients diagnosed with multi-vessel coronary artery disease at 20 European and US centers to either angiography-guided PCI (n=496) or FFR-guided PCI (n=509) all using current DES regimens. FAME’s objective was to compare angiographic guidance to FFR guidance and to determine which coronary lesions required revascularization. FAME demonstrated that FFR- guidance in routine multi-vessel PCI resulted in clinically-superior outcomes and reduced the composite of death, documented myocardial infarction, and repeat revascularization by 30 percent at one year. The study also demonstrated that adhering to an FFR-guided regimen for multi-vessel disease is cost beneficial to the hospital and payers by reducing procedural costs ($5,332 vs. $6,007), lowering average length of hospitalization (3.4 days vs. 3.7 days), and reducing the number of drug eluting-stents necessary per patient (1.9 vs. 2.7). The data also showed that the implementation of FFR did not add time to the multi-vessel PCI procedure.

DEFER

DEFER is a landmark study demonstrating that patients with intermediate disease not treated with PCI based on FFR guidance achieved long-term outcomes out to five years equivalent to patients who underwent PCI for similar intermediate lesions. DEFER outlines a revascularization strategy for angiographically equivocal stenoses that deploys FFR technology to identify and treat only those lesions producing reversible ischemia. The Journal of the American College of Cardiology has recognized the five-year follow-up results of the DEFER trial as one of the studies with the greatest impact on clinical cardiology in 2007. (JACC Vol. 51, No. 4, 2008 January 29, 2008:490-512)

PrimeWire(TM) and s5-FFR Option

Volcano is pleased to announce the launch of the new PrimeWire Pressure Guidewire, which is compatible with Volcano’s s5 family of integrated imaging consoles. Volcano’s PrimeWire was showcased yesterday at TCT in two live case demonstrations performed at Columbia Presbyterian Medical Center in New York and at Riverside Medical Center in Columbus, Ohio. “The launch of the PrimeWire underlines Volcano’s commitment to this very important Functional Measurement (FM) market and, in light of yesterday’s important presentation of the FAME study, we look forward to working with our customers to bring the PrimeWire and our state-of-the-art FFR technology to the benefit of patients,” said Scott Huennekens, Volcano’s President and Chief Executive Officer.

Volcano’s PrimeWire measures intracoronary pressure to derive an FFR index. FFR expresses maximum achievable blood flow in a coronary artery with the presence of an abnormal stenosis as a fraction of maximum blood flow achievable in the absence of a stenosis. FFR is 100% specific in identifying lesions actually restricting blood flow enough to cause ischemia.

Hospitals with Volcano’s s5 and s5i imaging consoles in the U.S. and Europe can now acquire the FFR functionality to support the PrimeWire and add this important tool to their existing IVUS system and workflow.

Joe Burnett, Associate Vice President, marketing commented, “Earlier- generation consoles included only one of the three technologies now available on the s5. If a hospital wanted to equip a new lab with all three technologies, they would have to acquire three separate consoles, each with a different measurement modality, training requirements and data storage protocols. The Volcano s5 can now accommodate the three primary intravascular diagnostic tools in regular use by cardiologists today (high frequency rotational IVUS, fast and simple digital IVUS, and pressure-based FFR guidewires) on a single platform, making modern day imaging consoles more flexible than ever before.”

About Volcano Corporation

Volcano Corporation offers a broad suite of devices designed to facilitate endovascular procedures, enhance the diagnosis of vascular and structural heart disease and guide optimal therapies. The company’s intravascular ultrasound (IVUS) product line includes ultrasound consoles that can be integrated directly into virtually any modern cath lab. Volcano IVUS offers unique features, including both single-use phased array and rotational IVUS imaging catheters, and advanced functionality options, such as VH(TM) tissue characterization and ChromaFlo(R). Volcano also provides functional measurement (FM) consoles and single-use pressure and flow guide wires and is developing a line of ultra-high resolution Optical Coherence Tomography (OCT) systems and catheters. Currently, more than 3,500 Volcano IVUS and FM systems are installed worldwide, with approximately half of its revenues coming from outside the United States. For more information, visit the company’s website at http://www.volcanocorp.com/.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Any statements in this release regarding Volcano’s business that are not historical facts may be considered forward-looking statements, including statements regarding the commercial prospects for, or potential customer use of, the PrimeWire Pressure Guidewire and the s5-FFR Option. Forward-looking statements involve risks and uncertainties and are based on management’s current expectations. Actual results could differ materially from these forward-looking statements as a result of certain factors, including the risks and uncertainties related to the development of new products and their commercial acceptance, and other factors discussed in Volcano’s filings with the Securities and Exchange Commission, including in its Annual Report on Form 10-K for the year ended December 31, 2007 and in its Quarterly Report on Form 10-Q for the quarter ended June 30, 2008. Undue reliance should not be placed on forward-looking statements, which speak only as of the time they are made. Volcano undertakes no obligation to update any forward-looking statements to reflect new information, events or circumstances, changed assumptions or otherwise. Actual results or experience could differ materially from the forward-looking statements.

Volcano Corporation

CONTACT: Sandra Mercer, Director of Marketing Communications of VolcanoCorporation, cell, +1-916-952-2133, [email protected]; Shalon Roth,Managing Director of Ricochet Public Relations, +1-212-679-3300, ext. 127,+1-917-952-1157, [email protected], for Volcano Corporation

Web site: http://www.volcanocorp.com/

Recovery From Pneumonia Aided By Steroids

Adding corticosteroids to traditional antimicrobial therapy might help people with pneumonia recover more quickly than with antibiotics alone, UT Southwestern Medical Center scientists have found.

Unlike the anabolic steroids used to bulk up muscle, corticosteroids are often used to treat inflammation related to infectious diseases, such as bacterial meningitis. Used against other infectious diseases, however, steroid therapy has been shown to be ineffective or even harmful.  

In a study available online and in a future issue of the Journal of Infectious Diseases, researchers at UT Southwestern show that mice infected with a type of severe bacterial pneumonia and subsequently treated with steroids and antibiotics recovered faster and had far less inflammation in their lungs than mice treated with antibiotics alone.

“Some people might think that if you give steroids, it would counteract the effect of the antibiotic,” said Dr. Robert Hardy, associate professor of internal medicine and pediatrics and the study’s senior author. “But it turns out you need the antibiotic to kill the bug and the steroid to make the inflammation in the lung from the infection get better. The steroids don’t kill the bugs, but they do help restore health.”

Pneumonia is a lung infection typically characterized by breathing difficulties and spread by coughing and sneezing. Symptoms include headache, fever, chills, coughs, chest pain, sore throat and nausea. Pneumonia caused by the Mycoplasma pneumoniae bacterium is generally a less severe form of the disease that can occur in any age group. It accounts for 20 percent to 30 percent of all community-acquired pneumonia cases.

In the current study, mice infected with the M  pneumoniae bacterium were treated daily with a placebo, an antibiotic, a steroid, or a combination of the antibiotic and steroid in order to investigate the effect on M  pneumoniae-induced airway inflammation. The animals were then evaluated after one, three and six days of therapy.

“It turns out that the group that got both the antibiotic and the steroids did the best,” Dr. Hardy said. “The inflammation in their lungs got significantly better.”

Although antimicrobials remain the primary therapy for M pneumoniae infection, there have been several reports in recent years about physicians adding steroids to the treatment regimen of patients with severe cases, Dr. Hardy said. The problem, he said, is that those were individual case reports.

“They never had a control group, so it was impossible to tell what impact the addition of steroids had on recovery,” he said.

The new findings not only suggest that giving antibiotics with steroids can help individuals with pneumonia get better faster, but also suggest a potentially more effective therapy for someone in the midst of an asthma attack due to M  pneumoniae infection. Up to 20 percent of asthma attacks in children and adults have been shown to be triggered by this bacterium.

Dr. Hardy said it’s too early to recommend steroids as standard treatment for people with this type of bacterial pneumonia, but the work does support the need for a clinical trial.

“Or if there are very sick patients, this combination treatment doesn’t seem to worsen the disease,” he said. “The good thing about our results is the data alone support moving on to a clinical study.”

Other UT Southwestern researchers involved in the study were Dr. Christine Salvatore, infectious-disease fellow in pediatrics; Dr. Chonnamet Techasaensiri, postdoctoral trainee in pediatrics; Dr. Asunci³n Mejías, assistant professor of pediatrics; Dr. Juan Torres, visiting senior researcher in pediatrics; Kathy Katz, senior research associate in pediatrics; and Dr. Ana Maria Gomez, assistant professor of pathology. Researchers from the University of Milan also contributed to the study.

The National Institutes of Health supported the work.

On the Net:

Doctor Selling Fake Viagra Jailed For Fraud

A multi-million dollar plot to sell fake medicines has landed a doctor in jail for three years.

Dr. George Patino plead guilty at Kingston Crown Court for selling thousands of counterfeit impotence tablets to customers via the web.

Known online as the “King of Viagra”, Patino, 48, who is a Mexican national with a US passport, was described a “disgrace to his profession” by the judge. He was also ordered to pay costs and had money confiscated.

As many as 200 Internet orders a day were placed for the fake Viagra tablets.

Patino, last year, stood trial alongside other members of a gang who were convicted of smuggling copies of Viagra and medicines to treat baldness from illegal factories in China, Pakistan and Asia.

A verdict was never reached on Patino and he was due to appear for a retrial, but last week entered a guilty plea to one charge.

According to court records, Patino was in league with the lynchpin of the operation Ashish Halai, 34, of Borehamwood, Hertfordshire, who was jailed for four-and-a-half years last year.

The fake medicines arrived in brown bottles rather than in the packaging used by manufacturer Pfizer.

The return address on the labels belonged to a Finnish post box number, listed to deliberately conceal the identities of those behind the operation.

The court heard E-mails from disgruntled customers complaining the tablets were fake, with some people saying they had suffered headaches and nausea.

Others complained they had no effect while another said the tablets were coated in blue paint that was coming off.

“As a highly intelligent man you must have been aware of the consequences of the illicit trade in Viagra,” asked Judge Nicholas Price QC.

“You must bear a heavy responsibility for your actions that were driven by greed and a reckless disregard for the effects of your criminality.

“Such conduct from a doctor of medicine goes against all medical ethics and makes you a disgrace within your profession.”

Patino was arrested in October 2005 at Heathrow Airport. He was carrying a laptop and memory stick containing files which revealed his business dealings as he waited for a plane to Leeds.

Also found were more than 2,000 digital photographs depicting or associated with pharmaceutical products.

The Medicines and Healthcare products Regulatory Agency (MHRA) prosecuted the case in an operation known as Stormgrand.

“Counterfeit medicines can be dangerous – designed so as to deceive people and healthcare professionals whilst generating vast profits for the counterfeiters,” said Mick Deats, group manager of enforcement at the MHRA.

“The MHRA will not hesitate to use the full range of powers available to investigate and prosecute those who represent a risk to public health.”

Patino was also ordered to pay £50,000 ($86,000USD) in costs, banned from being a company director for 10 years and had a sum of nearly £135,000 ($235,00USD) confiscated under the Proceeds of Crime Act.

Image Courtesy Wikipedia

Rising Demand for Interactive Patient Television Systems Drives LodgeNet Healthcare Sales Growth

SIOUX FALLS, S.D., Oct. 15 /PRNewswire-FirstCall/ — LodgeNet Healthcare, a newly created division of LodgeNet Interactive Corporation , today marked the rapid growth of its interactive hospital systems by announcing that it has now contracted with more than 35 hospitals for the sale and installation of its industry leading interactive system. In addition, with the recent creation of a separate division focused on the Healthcare market, Gary Kolbeck has been named General Manager, LodgeNet Healthcare.

(Logo: http://www.newscom.com/cgi-bin/prnh/20080115/AQTU120LOGO)

Major hospitals including Brigham & Women’s Hospital (Boston), Children’s Hospital of Pittsburgh and NorthShore University HealthCare (Chicago), among others, are turning to LodgeNet Healthcare to better manage patients’ needs and experiences, while helping to engage patients and encouraging them to become more involved in the care process. Beyond providing a variety of entertainment options that range from movies, music, and video games to interactive information delivery, LodgeNet Healthcare also helps hospitals tackle tough issues such as quality measures, patient satisfaction, and streamlined patient education delivery and compliance, by providing integration to their clinical systems. The intent of the education is to make the patient a knowledgeable participant in the healthcare process.

“As our Company continues to grow and evolve, the Healthcare Division is one of our major initiatives for expansion,” said Scott C. Petersen, Chairman and CEO. “We view the healthcare market as an outstanding opportunity for us given its size and its favorable competitive environment. The US market has more than one million hospital beds in operation, yet the presence of interactive systems is presently limited to just a few leading healthcare facilities.”

“Creating a separate division dedicated to our healthcare business enables us to efficiently and effectively serve our customers by focusing exclusively on their needs and concerns as it relates to education, safety and the patient experience,” continued Petersen. “We have a 28 year track record in providing reliable and easy-to-use interactive television services to address consumer demands, and have a LodgeNet employee-staffed 24x7x365 support operation which stands ready to support the needs of the healthcare industry.”

“I’m pleased to have the opportunity to lead this exciting division,” said Gary Kolbeck, General Manager, LodgeNet Healthcare. “What sets us apart is our commitment to each facility we serve. We partner with our healthcare customers to jointly evaluate which products and features will benefit the hospital and their staff, and then deploy a solution to meet the needs identified. As a true ‘integration’ company, we work with clinical systems like the EMR, ADT, physician order entry systems, dietary systems, and others to better involve the patient in their care. It’s the dedication and experience we bring to the table that make our clients and their patients happy, safe, and informed. The increasing number of hospitals choosing us since our launch and the positive impacts they have seen are evidence of the value of our system and service.”

“Since 2005, Gary has led LodgeNet’s healthcare initiative,” added Petersen. “He has been with LodgeNet for over 18 years, so he knows and understands the technology and benefits of interactive television extremely well. He has done an outstanding job in helping us extend LodgeNet’s consumer-driven market knowledge, integration capabilities, and service and support into the healthcare sector. The business has grown rapidly over the last year and I’m excited to have a person with Gary’s talents and dedication to lead this important and fast growing division.”

Well-respected hospitals recognizing value of interactive-TV

LodgeNet Healthcare brings its interactive TV market leadership into the healthcare space, with the ability to customize the system to be uniquely tailored to each hospital. The LodgeNetRX(TM) Interactive Patient Television System improves the experience for patients, guests and caregivers, and top-rated hospitals are taking notice.

“Patient care and satisfaction are our top priorities and the LodgeNetRX Interactive Patient Television System has been and will continue to be an important factor in addressing them,” said Jennifer Nadelson, administrative director, Brigham and Women’s Hospital. “We rely on LodgeNet Healthcare to help us create a branded interactive experience for patients that improves their experience and health. Equally as important, we depend on them for a system that is truly easy to use, reliable and supportable.”

The LodgeNetRX solution does not require an IP set-top or PC in the patient room, which has been shown to reduce support costs. LodgeNet’s knowledge of interactive television services and its years of experience integrating television systems to other back-end systems make LodgeNetRX a turn-key, future-proof decision.

To ensure full-service support of the LodgeNetRX Interactive Patient Television System, a nationwide team of professional service technicians are available 24/7 year-round, offering telephone support, and remote system diagnostics from the company’s headquarters as well as the ability to provide on-site service if required.

About LodgeNet Interactive

LodgeNet Interactive Corporation is the leading provider of media and connectivity solutions designed to meet the unique needs of hospitality, healthcare and other guest-based businesses. LodgeNet Interactive serves more than 1.9 million hotel rooms representing 10,000 hotel properties worldwide in addition to healthcare facilities throughout the United States. The company’s services include: Interactive Television Solutions, Broadband Internet Solutions, Content Solutions, Professional Solutions and Advertising Media Solutions. LodgeNet Interactive Corporation owns and operates businesses under the industry leading brands: LodgeNet, LodgeNetRX, and The Hotel Networks. LodgeNet Interactive is listed on NASDAQ and trades under the symbol LNET. For more information, please visit http://www.lodgenet.com/.

LodgeNet and LodgeNetRX are trademarks or registered trademarks of LodgeNet Interactive Corporation. Other trademarks are the property of their respective owners.

Photo: http://www.newscom.com/cgi-bin/prnh/20080115/AQTU120LOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, [email protected]

LodgeNet Interactive

CONTACT: Ann Parker, Director of Corporate Communications of LodgeNetInteractive Corporation, +1-605-988-1000, [email protected]; orInvestors, Mike Smargiassi, [email protected], or Media, Ray Yeung,[email protected], both of Brainerd Communicators, for LodgeNet Interactive,+1-212-986-6667

Web site: http://www.lodgenet.com/

AtStaff Announces That The University of Virginia Medical Center Has Selected ClairVia(R) Staff and Demand Management Software to Support Its Mission of Excellence and Innovation in Patient Care

AtStaff, Inc., announces today that the University of Virginia Medical Center, a nationally renowned academic medical center and Magnet designated organization, has selected AtStaff’s ClairVia(R) staff and demand management solutions in support of its ongoing mission to provide excellence and innovation in patient care.

The University of Virginia Medical Center, an integrated network of primary and specialty care services anchored by a 500-bed hospital and state-designated Level 1 trauma center, will implement three ClairVia solutions:

— ClairVia(R) Demand Manager – Leverages patient-tracking and flow management technology to measure, monitor and predict patient-specific care demand

— ClairVia(R) Caregiver Assignment – Selects and assigns specific caregivers based on each patient’s individual care and workload needs

— ClairVia(R) Staff Manager – Facilitates day-to-day staffing coverage, allocation and deployment based on demand requirements.

“As an academic medical center and a Magnet organization, the University of Virginia strives for excellence in patient care every day,” says Dr. Pamela Cipriano, PhD, RN, FAAN, NEA-BC, Chief Clinical Officer and Chief Nursing Officer at the University of Virginia Health System. “We have a number of systems that collect and store data, but they are not integrated to allow for meaningful analysis. The ClairVia suite of software products gives us the ability to integrate and analyze staffing data together with patient volume and outcomes data. This information will enable data-driven decisions at all levels.

“ClairVia’s robust reporting functions provide managers with the tools for improved resource utilization, and our staff gain the ability to control their schedules. It’s a win for everyone.”

Beth Pickard, President and Chief Executive Officer at AtStaff, says: “AtStaff is extremely honored to serve The University of Virginia Medical Center, one of the nation’s finest academic medical centers with an exceptional reputation for delivering outstanding patient care. We embark on this exciting opportunity in a true partnership spirit as both organizations are focused on the same vital and fundamental objective: benefiting human health by achieving positive patient outcomes and advancing the quality of life.”

UVa Medical Center to rely on ClairVia solutions to transform its staffing care delivery, meet growing performance-driven requirements, and participate in industry-leading nursing research initiatives

“AtStaff’s commitment to improving care quality and patient safety, its leadership in nursing care research, its superior technology, and its ability to forge strong relationships were all key factors in our decision,” says Terri Haller, MBA, MSN, NEA-BC, RN, Director of Business Operations and Workforce Development, Clinical Care Services, at the University of Virginia Medical Center.

Haller, who took a leadership role in UVa’s vendor selection process and serves as the ClairVia project director, explains that the implementation of ClairVia solutions is central to the medical center’s transformational efforts in healthcare staffing and care delivery. She says UVa will rely on ClairVia to achieve the following organizational goals in its redesign initiative:

— Improve patient safety

— Improve the efficiency of staffing operations, specifically by:

— Better managing patient flow

— More accurately aligning staffing workload to patient demand

— Matching caregiver characteristics to patient-specific needs

— Reducing “reactive” decision-making by predicting demand variables

— Enhance the organization’s ability to recruit and retain quality staff

— Increase operating margins

“ClairVia solutions directly address what I would refer to as ‘a perfect storm’ in healthcare,” emphasizes Haller. “Declining reimbursements, coupled with non-payment for Hospital Acquired Conditions and emphasis on patient throughput are challenges that all organizations face. It is essential for organizations to have information and tools to manage patient care and staffing resources in a fiscally responsible manner.”

Haller points out that ClairVia’s outcomes-based and evidence-driven capabilities provide the data needed to make long-term, lasting improvements in patient outcomes and healthcare delivery.

“For instance, because ClairVia measures the type of individualized care and the amount of nursing intensity each patient receives, it can assess the outcomes implications occurring at these critical caregiver and patient connections. This has great potential to move nursing practice ahead, and transform how nursing care is viewed and reimbursed.”

UVa is one of many leading healthcare organizations that have agreed to participate in a national research study sponsored by AtStaff that will examine the relationships among nurse staffing, nurse-specific characteristics and clinical and cost outcomes.

“AtStaff’s academic approach and its orientation toward nursing research and best practice really impressed us as an organization,” Haller says. “We are excited to be a part of this ground-breaking research, along with other AtStaff customers, that could help shape the future of nursing care and reimbursement models.”

She indicates that ClairVia, because of the quality and relevance of the information it gathers as well as through its advanced automation, will be immensely helpful in preparing and furnishing data to organizations such as the American Nurses Credentialing Center, The Joint Commission and other benchmarking or regulatory entities.

“It’s going to be a great help to us because we’ll not only have real-time decision support for daily staff management, but we’ll have the easily accessible data for all of our reporting purposes.”

ClairVia Demand Manager & ClairVia Caregiver Assignment

“We view both ClairVia Demand Manager and Caregiver Assignment as basically one module because together they automate the critical connection between each patient’s clinical requirements and the staffing resource available and qualified to meet that requirement,” Haller explains. “These products provide the patient demand and staffing information — in a completely integrated manner — that our managers need each day to meet patient care requirements and improve patient throughput.”

Through HL-7 integration with hospitals’ ADT systems, ClairVia Demand Manager tracks and compares each patient’s real-time movement through each phase of care against an outcomes-based, individualized patient progress pattern.

“Another factor that attracted us to Demand Manager is its predictive capabilities,” Haller says. “Demand Manager proactively identifies outliers and other variables of patient demand so we can pinpoint what staffing resources that will be needed days ahead, not just shifts ahead.”

UVa’s future plans include integrating its EMR with Demand Manager so that patient progress patterns reflect patient-specific clinical data and assessments, in addition to ADT data.

The final step in patient-focused staffing is matching each caregiver’s background, including specific competencies, certifications and professional development qualities, to each patient’s clinical requirements — the role of ClairVia Caregiver Assignment.

“We’re excited about implementing Caregiver Assignment,” Haller says. This software allows us to make staffing assignments based on the best fit between each caregiver, their competencies and skill level, with each patient,” Haller says. “This module has great potential to help providers report on and analyze the merits and effectiveness of different caregiver-to-patient linkages. This is particularly important given the mounting pressures on healthcare providers to demonstrate quantifiable improvements in care, quality and performance metrics.”

ClairVia Staff Manager

The University of Virginia Medical Center also will be relying on ClairVia Staff Manager for day-to-day staff management, including enterprise scheduling and staffing, real-time decision support, and advanced productivity measurement and reporting.

In addition to ensuring that staffing resources are aligned based on patient demand tracking and prediction, ClairVia Staff Manager provides comprehensive communication capabilities for healthcare stakeholders via personalized dashboards.

For employees, the dashboards provide the means for constant communication, interaction and collaboration. At any time and place, they can submit schedule requests, sign up for “shift opportunities” (available open shifts), exchange shifts with colleagues, and view their current and future schedules.

“The personalized dashboards in Staff Manager give everyone an easy-to-use, front-and-center point of control for scheduling and staffing,” notes Haller. “Managers have the peace of mind of knowing that all the employees available and interested in working extra time can easily sign up for open shifts, and discover all their options. Staff will gain the ability to go online, and gain more control over their schedules.”

Nicole Henley, a clinician who serves as a scheduler in an intensive care unit at UVa, says she’s eager to begin using ClairVia Staff Manager.

“The system is really user-friendly and intuitive,” expresses Henley, a clinician who serves as a scheduler in UVa intensive care unit. “Staff will be able to access schedules from work and home, and identify colleagues for shift swaps. This system will save tons of time for schedulers, managers, and staff.”

Software ease of use, Haller adds, is essential as UVa employees will be depending on the system every day.

“Even with all of its innovation, the key thing that impresses our people — and certainly impressed our vendor selection committee, which included a very broad mix of staff managers, clinicians and schedulers in different disciplines — is that ClairVia software is easy-to-use and user-friendly software.”

About the University of Virginia Health System

One of the nation’s leading medical research centers, UVA Health System is located in Charlottesville and has five components: the Medical Center, the School of Medicine, the School of Nursing, the Claude Moore Health Sciences Library and the Health Services Foundation.

The Medical Center is an integrated network of primary and specialty care services ranging from wellness programs and routine checkups to the most technologically advanced care. The hub of the Health System is a hospital with over 550 beds and a state-designated Level 1 trauma center.

For more information, visit www.healthsystem.virginia.edu/toplevel/home/home.cfm

About AtStaff

AtStaff develops demand management and staff management software that enables healthcare organizations to improve healthcare quality and patient safety, increase profitability, and enhance staff recruitment and retention. Hospital enterprise solutions and physician scheduling systems from AtStaff serve more than 1,200 healthcare organizations, medical facilities, nursing departments and group practices.

For more information, visit www.atstaff.com

BK Medical Systems, Inc. And Amerinet Announce New Three-Year Agreement

BK Medical Systems, an innovative leader in medical ultrasound and wholly owned subsidiary of Analogic Corporation, (NASDAQ: ALOG), has signed a new three-year, product line agreement with Amerinet Inc. (www.amerinet-gpo.com), a leading health care group purchasing organization. Amerinet partners with more than 27,000 healthcare providers nationwide to reduce costs and improve quality. This agreement makes BK Medical’s surgical ultrasound systems, related accessories, and supplies available to Amerinet members.

For almost 30 years, BK Medical Systems has manufactured ultrasound scanners specially designed for surgery and for the investigation of urological disorders. BK Medical is the ultrasound market leader in the fields of prostate scanning, brachytherapy, and intraoperative and laparoscopic surgery. Our core capabilities in image quality, system engineering, beam forming, and transducer design are fundamental to all our products.

BK Medical recently announced the launch of the Pro Focus OR Ultrasound system, the only fully featured operating room suite that is mounted on the OR boom, affording the OR staff their accustomed freedom of movement within the sterile area. Surgeons can access all the system’s capabilities inside the sterile zone using a Palm Control Unit.

BK Medical employs knowledgeable ultrasound sales specialists and supports its clients with a dedicated team of highly skilled clinical education specialists and factory-trained field service engineers. For more information about BK Medical and its ultrasound solutions, please call (800) 879-7226 or visit us at www.bkmed.com.

About Amerinet

As a leading national group purchasing organization, Amerinet strategically partners with healthcare providers to reduce costs and improve quality. Through its Total Spend Management solutions and operational performance improvement programs, tools and services, Amerinet assists members in their efforts to reduce costs, improve efficiencies and create new revenue streams. Supported by a team of clinical, data and supply chain experts, Amerinet offers a comprehensive portfolio of product and service contracts to address members’ specific needs. Based in St. Louis with offices in Salt Lake City, Providence, R.I., and Warrendale, Pa, BK Medical Systems Inc: 250 Andover Street – Wilmington, Massachusetts 01887 -USA – Tel.: 800-876-7226 – Fax: 978-988-1478 – www.bkmed.com

Amerinet serves acute and non-acute healthcare providers nationwide. To learn more, visit www.amerinet-gpo.com

Facts about B-K Medical

B-K Medical ApS, a wholly owned subsidiary of Analogic Corporation (NASDAQ: ALOG), specializes in the development and production of diagnostic ultrasound equipment. The company is recognized as a world leader in developing ultrasound scanners specially designed for surgery and for the investigation of urological disorders. The product line also includes scanners for other applications, such as gynecological examinations, fetal scanning, and radiology.

B-K Medical is represented in 60 countries, with subsidiary sales companies in the U.S., Belgium, Germany, Italy, Norway, Sweden and the U.K. An extensive network of distributors connects B-K Medical with Eastern Europe, the Middle East, Asia and the rest of the world. The company has about 300 employees, of which about two-thirds are located in Denmark.

Alzheimer’s Expert Urges Boomers to Think About Their Cognitive Health Now

HOUSTON, Oct. 15 /PRNewswire/ — While a study in the October 15, 2008 JAMA demonstrates that B vitamins do not slow cognitive decline once Alzheimer’s disease has struck, there is a large body of scientific evidence showing that some nutrients may help keep the brain healthy as one ages. A leading expert thinks the time is now for Baby Boomers to look seriously at maintaining cognitive wellness. According to the Alzheimer’s Association, 10 million Boomers can expect to get Alzheimer’s disease as they age.

“There are many things like heredity that are outside our control, but there are also concrete steps we can take to maintain optimal brain health,” says Marwan Sabbagh, MD, FAAN, a leading Alzheimer’s researcher and physician who has written extensively on the disease. “The time to think about this is long before memory problems start.”

Dr. Sabbagh has looked exhaustively at published research on Alzheimer’s disease and brain health, and he has identified a number of important factors in maintaining cognitive wellness. Among the modifiable risk factors for Alzheimer’s are hypertension (high blood pressure), high cholesterol, high homocysteine levels, diabetes-elevated insulin levels, and obesity, especially during midlife.

There is also evidence that dietary modifications can help maintain cognitive wellness. Combing through published research on the topic, Dr. Sabbagh has identified a group of nutrients that have strong evidence of protective effects.

“The use of these nutrients to support cognitive wellness is well documented in the scientific literature,” says Dr. Sabbagh. “The JAMA article underscores the need to consider supplementation long before disease starts.”

To help American consumers make good supplement choices, Dr. Sabbagh worked with AmeriSciences, a leading science-based nutraceutical company, to develop a formulation that includes ingredients with strong scientific merit. AmeriSciences’ Cognivite Complete was specially formulated under Dr. Sabbagh’s guidance to provide nutritional support to help combat declining mental function and memory loss associated with aging. Dr. Sabbagh’s expertise in this area led AmeriSciences to recently appoint him to chair the company’s Scientific Advisory Board.*

Cognivite Complete’s ingredients include: Gingko biloba; docosahexaenoic acid (DHA); turmeric root (curcumin); and phosphatidylserine. Gingko biloba helps maintain normal blood flow to the brain and is rich in flavonoid antioxidants, which may offer protection against neuron damage.** Turmeric root, a common spice in Asia and a constituent of many curries, has been shown to exhibit a variety of protective effects in the brain, from stimulation of normal anti-inflammatory functions to the reduction of natural oxidative damage.** DHA, an omega-3 fatty acid, is a vital component of the cell membranes of the brain. Studies suggest that it may help overall cognitive maintenance.** Phosphatidylserine is a fat derivative (phospholipid) found in soybeans and other foods, which is involved in brain signal activity and is an important part of neuronal membranes.**

According to Dr. Sabbagh’s research, a modest decline in cognitive health is an expected part of the aging process; however, this decline can be exacerbated by factors such as poor nutritional habits and stress. Through lifestyle modifications and a consistent nutritional regimen that includes supplementation, Dr. Sabbagh believes people can help preserve normal brain function and ensure cognitive wellness.

Dr. Sabbagh serves as Chief Medical-Scientific Officer and Director of Clinical Research at the Sun Health Research Institute, Sun City, Arizona.*

For more information on Cognivite Complete, please visit http://www.amerisciences.com/ or http://www.cognivite.com/.

* Disclosure: Dr. Sabbagh receives royalties from sales of Cognivite Complete, and is in a partnership that distributes AmeriSciences products. Dr. Sabbagh’s relationship with AmeriSciences is separate from his work with Sun Health.

** These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease. Consult with your physician before taking any nutritional supplement.

AmeriSciences

CONTACT: Dennis Tartaglia of Widmeyer Communications, +1-646-213-7246,[email protected], for AmeriSciences

Web Site: http://www.amerisciences.com/http://www.cognivite.com/.

ICS Software, Ltd.’s CheckMedicare.Com Informs Doctors If Their Patients Opt Out of Medicare

ICS Software, Ltd. is proud to give doctors the ability to check their patients’ Medicare Part A and B eligibility and deductible status through a website called www.CheckMedicare.com. In just a few seconds, the Doctor retrieves results that will have a direct positive impact on the practice and will increase cash flow. For only 25 cents per eligibility check, CheckMedicare.com is an easy business solution to ensure the billing of a doctor’s service is rendered.

To use CheckMedicare.com, simply type the patient’s Medicare number, date of birth, first name, last name, and date of service. Results include a Medicare patient’s eligibility status, remaining deductible amount, HMO/PPO/Indemnity the patient switched to, or if Medicare is the secondary insurance. The site retains a three-month history of eligibility checks and also provides information regarding how many skilled nursing home, smoking cessation, and home health care days remain.

The CEO of ICS Software, Ltd. Ken Katz states, “Doctors are now starting to feel the effects of the HMOs on their bank accounts. Medicare patients are switching out of Medicare and transferring to an HMO for the cost of a bagel. This service will save the staff time that could be better spent going after accounts receivables, and save the doctors money because now they are getting accurate real time information.”

CheckMedicare.com is available nationwide, 24 hours a day, 7 days a week. Register today and check 10 patients for FREE. Checking the eligibility of your Medicare patients will save your practice thousands of dollars per year.

About ICS Software, Ltd.

ICS Software, Ltd. has been serving the Medical Community since 1986. It provides Doctors and their staff with time saving and easy to use programs to enable them to run their practice with ease and increase income.

 Contact: Email: Email Contact Phone: 877-624-3250 Web: www.CheckMedicare.com

SOURCE: ICS Software, Ltd.

Cogent’s Shaun Frost, M.D. Contributor to New Textbook on Hospital Medicine

Cogent Healthcare is pleased to recognize Shaun Frost, M.D., Regional Medical Director, for his contribution to a recently published textbook targeting the practicing hospitalist, entitled Just the Facts in Hospital Medicine.

Just the Facts in Hospital Medicine provides readers with expert, up-to-date coverage of unique, need-to-know concepts in hospital medicine, including key clinical, organizational and administrative issues. The book is authored by Sylvia McKean and was published this summer by McGraw-Hill.

“Literature such as this plays an important role in further defining the specialty of hospital medicine, and on behalf of Cogent, I commend Dr. Frost for his involvement,” said Gene Fleming, President and Chief Executive Officer of Cogent Healthcare. “His work exemplifies the influence Cogent leaders continue to have in shaping the field of hospital medicine.”

Dr. Frost’s contribution appears in the section entitled “Hospitalist as Medical Consultant” and specifically addresses topics related to surgical comanagement. Dr. Frost also contributed chapters to an earlier book in the “Just the Facts” series entitled, Just the Facts in Perioperative Medicine published in 2006.

“I am honored to be a part of this project that will serve as a comprehensive resource for those in my field,” said Dr. Frost. “This book is important because it defines both clinical and operational disciplines of hospital medicine based on the core competencies developed by the Society of Hospital Medicine.”

“Especially practical is how the book successfully addresses healthcare systems integration issues that are universally germane to the practicing hospitalist, such as leadership and teamwork, quality and process improvement, management of care transmissions, and hospitalists as teachers,” said Dr. Frost.

Dr. Frost joined Cogent in 2006 and oversees the company’s programs in the eastern region of the United States. Previously, he worked in Minneapolis at HealthPartners Medical Group and Clinics, where he led a number of process and quality improvement initiatives. As a prior faculty member at the medical schools of the University of Minnesota and the Pennsylvania State University, he has spoken and published extensively on a variety of healthcare topics. Dr. Frost is a board member of Society of Hospital Medicine and a Fellow of the American College of Physicians. He received his medical degree from The University of Texas Southwestern Medical School at Dallas.

About Cogent Healthcare

Cogent Healthcare is a leading provider of hospitalist programs. Its focus is to relentlessly improve the care and efficiency of hospitalized patients by reducing variations in care, establishing best practices, identifying and removing barriers to efficient care and measuring outcomes. To this end, the company provides a comprehensive System of Care(TM) to its hospital partners that supports its hospitalists in the delivery of inpatient care and includes structure, a coordinated care team, data driven processes, rigorous ongoing training and experienced leadership. Cogent physicians continue to lead the profession by setting best practices for hospital medicine and providing a national mentoring program. For more information about Cogent Healthcare, visit www.cogenthealthcare.com.

Symposium, Patient Reunion Will Help Mark 40 Years of Pioneering Work in Heart Transplantation at Stanford

The afternoon Elizabeth Craze was born 26 years ago, her parents held their breath.

“She is perfect,” the doctor told them.

But within four months, Elizabeth, like the four siblings before her, would be diagnosed with heart failure. Three had already died in infancy. The fourth, her older brother Andrew, would be diagnosed shortly after Elizabeth. It was thought to be a death sentence.

“I thought I would go absolutely insane,” said her mother, Susan Craze.

This was still the early days of heart transplantation surgery, especially for children. But there was no other choice for the Craze family, and the only place to go was Stanford.

“When I told my doctor in Cleveland we were considering heart transplantation, I can still picture him, backing up against the wall with just this look of horror on his face,” Susan Craze recalled.

Forty years ago in 1968, the late Norman Shumway, MD, and a team of doctors performed the first successful heart transplant in the United States at Stanford Hospital on a 54-year-old steelworker from East Palo Alto amid an uproar of controversy and a media frenzy. Proving the naysayers and skeptics wrong, the landmark operation has since become almost routine, saving thousands of lives around the world.

“We both stood there and stared into this huge empty cavity for a good half a minute,” said Edward Stinson, MD, who assisted Shumway in carving out the diseased heart in that first transplant surgery. “It was a fairly awesome sight. ‘Do you think this is really legal?’ I said.”

The goal from the beginning wasn’t scientific experimentation but to save lives, said Stinson, professor emeritus of cardiothoracic surgery at the Stanford University School of Medicine. To save lives like those of Elizabeth and her brother Andrew.

“It was in no way simply a stunt,” said Stinson. “There was no denying there was controversy about the procedure, but we could foresee what the potential was. The underlying ambition was always to improve the quality of life and to extend life.”

Transplant survivors and scientific experts in the field of transplantation will travel to Stanford Oct. 24 for a symposium titled “Looking to the Future: 40 Years of Heart and Lung Transplantation at Stanford University” to commemorate the event and to explore the future science of heart and lung transplantation (see full schedule below).

Among those survivors will be Elizabeth Craze, now 26 years old, an IT employee working for Facebook in Palo Alto who at the age of 2 years and 10 months was one of the youngest successful heart transplant recipients in the world.

“I think I’m more grateful about life than most people,” said Craze, dressed in red Keds and a gray “Geeks for Obama” sweatshirt on a break from work. “I get excited about the littlest things.”

Craze, who celebrated the 24th anniversary of her heart transplant operation this month, has taken medications all her life, struggled with the drugs’ side effects that gave her hairy eyebrows during her teen years, and resulted in a kidney transplant operation 10 years ago. But she looks and feels so healthy that friends are always shocked when they find out she’s had a heart transplant.

“You wouldn’t know there’s a thing wrong with her,” said Susan, her mother, who moved the family from Cleveland to the Peninsula to be near Stanford in 1989. Elizabeth’s older brother Andrew, 41, had the first heart transplant operation in the family, a year before Elizabeth when he was 16. Today he’s a mechanical engineer living in Cleveland.

Because there was no Lucile Packard Children’s Hospital at the time, both Andrew and Elizabeth received their new hearts at Stanford Hospital.

“My brother-in-law was the first to tell us about Stanford and how Dr. Shumway had continued the heart transplantation program even though so many medical facilities couldn’t do it,” Susan Craze said. “Stanford’s team was just so on top of everything. It was amazing.”

Part of the success of the Stanford and Packard programs continues to be their multidisciplinary team approach to patient care, which includes nurses, social workers and physicians. Social workers and nurses committed themselves to Elizabeth’s care after the operation, Susan Craze said. During the month-long recovery period, they worked overtime, took the girl trick-or-treating on the hospital ward and camped out by her bedside.

“We could foresee what the potential was for creating a multidisciplinary team approach to treatment,” Stinson said. “The whole idea was to transform what was brand-new technology into routine therapeutics.”

Advancements in the years following that first successful operation paved the way for future patients. New developments were made, many emanating from Stanford, in anti-rejection drugs, techniques for predicting organ rejection and ways to care for patients after transplants. New laws would define death based on brain function rather than heart function so that beating hearts could be extracted from brain-dead patients.

“I remember harvesting a child’s heart in North Dakota one night in 1986,” Stinson said. “We preserved that heart for a good eight hours. It was a world’s record at that time.”

Another heart procurement, this one carried out by Shumway, involved a homicide victim in Oakland. A defense lawyer claimed the death was caused by removing the victim’s heart after brain death had been declared. The legal opinion helped clear the way for heart extraction from brain-dead patients. The defendant was ultimately found guilty, Stinson said.

In 1984, when Elizabeth Craze showed up at Stanford in need of a new heart, the primary question was whether a donated heart would continue to grow along with her body. She was deathly ill and weighed only 23 pounds. An ethics committee was formed and, after listening to her brother’s pleas, the decision was made to go ahead with the operation.

“It was difficult trying to find a donor,” Susan Craze said. “It was really close whether she was going to make it another day.” On Oct. 8, 1984, the healthy heart of a little girl from Utah, the victim of a car crash, was transplanted into Elizabeth’s chest.

“My parents told my brother and me we could have whatever we wanted after surgery. I asked for pink ballet shoes,” Elizabeth said. “Andrew said he wanted the car. He got the brown Volvo.”

Susan Craze got her two children given back to her.

“I don’t think I could have survived them dying,” she said.

“Looking to the Future: 40 Years of Heart and Lung Transplantation at Stanford University” — an Oct. 24 symposium at Stanford

Schedule of events:

— 7:30 a.m. — Registration

— 8 a.m. – noon — Scientific symposium

— 12:15 – 1:10 p.m. — Live interview about the first heart and heart-lung transplants with Edward Stinson, MD, professor emeritus of cardiothoracic surgery at Stanford, who assisted the late Norman Shumway, MD, in the first successful U.S. heart transplant; and Bruce Reitz, MD, the Norman E. Shumway Professor of Cardiothoracic Surgery at Stanford, who with Shumway performed the world’s first heart-lung transplant.

— 2-4 p.m. — Transplant recipient reunion

Speakers and topics during morning symposium:

— “40 years of progress in the treatment of heart failure,” Michael Fowler, MD, professor of cardiovascular medicine, Stanford.

— “Mechanisms of idiopathic dilated cardiomyopathy,” Michael Bristow, MD, professor of medicine, University of Colorado.

— “The future of mechanical circulatory support,” Peer Portner, PhD, consulting professor of cardiothoracic surgery, Stanford.

— “Effects of pediatric heart disease on adult heart failure and transplant,” Daniel Murphy, MD, professor of pediatric cardiology, Stanford.

— “The next generation of immunosuppression drugs,” Randall Morris, MD, professor emeritus of cardiothoracic surgery, Stanford.

— “The future of transplantation immunology,” Philip Halloran, MD, PhD, professor of medicine, University of Alberta.

— “The evolving challenge of infection in the setting of cardiac transplantation: 40 years of Stanford contributions,” Jose Montoya, MD, associate professor of infectious diseases and geographic medicine, Stanford.

— “Mechanisms of cardiac allograft coronary artery disease,” Hannah Valantine, MD, professor of cardiology, Stanford.

— “Future treatment strategies for antibody-mediated cardiac rejection,” Adriana Zeevi, PhD, professor of immunology, University of Pittsburgh.

Stanford University Medical Center integrates research, medical education and patient care at its three institutions — Stanford University School of Medicine, Stanford Hospital & Clinics and Lucile Packard Children’s Hospital. For more information, please visit the Web site of the medical center’s Office of Communication & Public Affairs at http://mednews.stanford.edu.

Stanford Hospital & Clinics is known worldwide for advanced treatment of complex disorders in areas such as cardiac care, cancer treatment, neurosciences, surgery, and organ transplants. Ranked #16 on the U.S. News and World Report annual list of “America’s Best Hospitals,” Stanford Hospital & Clinics is internationally recognized for translating medical breakthroughs into the care of patients. The hospital is part of the Stanford University Medical Center, along with the Stanford University School of Medicine and Lucile Packard Children’s Hospital. For more information, visit www.stanfordhospital.com.

Ranked as one of the best pediatric hospitals in the nation by U.S. News & World Report, Lucile Packard Children’s Hospital at Stanford is a 272-bed hospital devoted to the care of children and expectant mothers. Providing pediatric and obstetric medical and surgical services and associated with the Stanford University School of Medicine, Packard Children’s offers patients locally, regionally and nationally the full range of health-care programs and services — from preventive and routine care to the diagnosis and treatment of serious illness and injury. For more information, visit http://www.lpch.org.

(NOTE TO REPORTERS: If you are interested in covering either the heart transplant symposium the morning of Oct. 24 or the transplant patient reunion that afternoon, please contact one of the media representatives listed above so that they can add your name to the guest list.)

Vigil Health Solutions and Vocollect Healthcare Systems Announce Strategic Reseller Agreement

PITTSBURGH, Oct. 15 /PRNewswire/ — Vocollect Healthcare Systems, Inc. and Vigil Health Solutions, a leading provider of healthcare products for the long-term care industry in North America, including nurse call systems, wireless call, bed monitoring, resident check in and the award-winning Vigil Dementia System, announce an agreement where Vigil will resell AccuNurse voice-assisted care as part of its long-term care solutions offerings to its customer base.

AccuNurse gives caregivers the option to access resident care needs on-demand, complete documentation of care simply by talking, enhance care-team collaboration with the Silent Page(TM) capability, and track improved clinical outcomes.

“Communities around the country are looking for solutions that take standards of care to higher levels, provide options to manage risk, and improve staff efficiency,” said Troy Griffiths, president and CEO of Vigil Health Solutions. “Voice-assisted care is a natural complement to our portfolio of emergency and nurse call solutions, enabling clients to provide a full continuum of care through the use of unobtrusive systems. The industry is demanding more homelike environments and we believe no other portfolio of solutions delivers this like Vigil plus AccuNurse.”

“We’re excited about our agreement with Vigil Health Solutions,” said James Quasey, president of Vocollect Healthcare Systems. “With great sensing and call technology offered by Vigil, plus personalized service with voice- assisted care, caregivers will use technology to their advantage like never before. Communities now have the tools to stay on top of resident needs, in real time, knowing caregivers have the information they need — right in their ears. By complementing their adaptable solutions with AccuNurse, we believe Vigil now offers the most advanced solution in the delivery of care, as well as opening a potentially significant new channel for revenue growth.”

About Vigil Health Solutions

Vigil (TSX-VEN: VGL) offers a proprietary technology platform combining software and hardware to provide comprehensive solutions to the expanding aged care market. Vigil has established a growing presence in North America and an international reputation for being on the leading edge of systems design and integration. The Vigil Integrated Care Management System(TM) (Vigil(R) System) includes the award-winning Vigil Dementia System, a nurse call system, bed monitoring, resident check in, and the latest development the Vigil Wireless call system. The first to supply dementia specific care technology, Vigil facilitates the highest standard of care for cognitive residents while helping dementia residents enjoy a higher quality of life and greater dignity. http://www.vigil.com/

About Vocollect Healthcare Systems

AccuNurse(R) voice-assisted care from Vocollect Healthcare Systems, Inc. makes it easy for healthcare professionals to retrieve care needs on-demand, chart activities as they are completed, and Silent Page(TM) each other for help — simply by talking. Organizations using AccuNurse benefit from lower operating costs, maximized reimbursements and improved quality of care. Vocollect Healthcare Systems is a subsidiary of Vocollect, Inc., the global leader in Voice-Directed Work and delivering performance improvements in productivity, accuracy, cost reduction and worker satisfaction for mobile employees on six continents.

Vocollect is a registered trademark of Vocollect, Inc.; AccuNurse is a registered trademark of Vocollect Healthcare Systems. http://www.accunurse.com/

Certain statements contained in this news release that are not based on historical facts, may constitute forward-looking statements or forward-looking information within the meaning of applicable securities laws (“forward-looking statements”). These forward-looking statements are not promises or guarantees of future performance but are only predictions that relate to future events, conditions or circumstances or our future results, performance, achievements or developments and are subject to substantial known and unknown risks, assumptions, uncertainties and other factors that could cause our actual results, performance, achievements or developments in our business or in our industry to differ materially from those expressed, anticipated or implied by such forward-looking statements.

Forward-looking statements include all financial guidance, disclosure regarding possible events, conditions, circumstances or results of operations that are based on assumptions about future economic conditions, courses of action and other future events. We caution you not to place undue reliance upon any such forward-looking statements, which speak only as of the date they are made. These forward-looking statements appear in a number of different places in this release and can be identified by words such as “may”, “estimates”, “projects”, “expects”, “intends”, “believes”, “plans”, “anticipates”, or their negatives or other comparable words. Forward-looking statements include statements regarding the outlook for our future operations, plans and timing for the introduction or enhancement of our services and products, statements concerning strategies or developments, statements about future market conditions, supply conditions, end customer demand conditions, channel inventory and sell through, revenue, gross margin, operating expenses, profits, forecasts of future costs and expenditures, and other expectations, intentions and plans that are not historical fact.

Forward-looking statements are based on management’s current plans, estimates, projections, beliefs and opinions and, except as required by law, Vigil does not undertake any obligation to update forward-looking statements should the assumptions related to these plans, estimates, projections, beliefs and opinions change.

The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release

Vocollect Healthcare Systems, Inc.

CONTACT: Jennifer Clement of Vocollect Healthcare Systems,+1-412-825-5336, [email protected]; or Michelle Leduc of VigilHealth Solutions, +1-877-850-1122, [email protected]

Web site: http://www.accunurse.com/http://www.vigil.com/

Palladian Chief Clinical Officer to Speak at Back Pain Panel Discussion NASHO Leadership Summit

WEST SENECA, N.Y., Oct. 15 /PRNewswire/ — Palladian Health, a comprehensive, muscular skeletal service provider that integrates physical therapy, chiropractic and physical health and fitness with primary care to establish optimal outcomes for health plans and their members, announced today it will exhibit and be a sponsor at the National Association of Specialty Health Organizations (NASHO) 6th Annual Leadership Summit in Las Vegas, Nevada, Tuesday, and Wednesday, October 21 and 22, 2008.

Kevin Cichocki, D.C., Palladian’s Chief Clinical Officer, will join a panel of experts, including John M. Ventura, D.C., DABCO, and Mina Harkins of NCQA, to discuss improving the quality and efficiency of back pain care. A practicing clinician, Dr. Cichocki founded Palladian in 1995 and serves as Board Chairman of the Erie County Medical Center in Buffalo, New York. Palladian’s focus is on medical specialties that address muscular skeletal injuries in conjunction with ongoing wellness and care coordination. This integrated clinical approach facilitates optimum health outcomes which result in high levels of satisfaction and cost savings for members, providers and health plans.

NASHO’s 6th Annual Leadership Summit is the largest specialty health industry event of the year. Other speakers at the event include Kristin Begley, Pharm.D., of Hewitt Associates; Michael Byrd of American Specialty Health; Richard Bedrosian, Ph.D., of HealthMedia; Valarie Borow, M.D., of HealthHelp; Neal S. Sofian of Resolution Health; Christine O. Leush, L.M.F.T., CEAP of Value Options; Dogu Celebi, M.D., of Ingenix; and Dee W. Edington of the University of Michigan, Health Management Research Center.

“In addition to supporting the growth of specialty health organizations, NASHO works closely with leading industry associations such as the AAPPO to advance and evolve specialty health care delivery,” said Kevin Cichocki, D.C., “Education is an important part of that process and I am pleased to be a part of NASHO’s efforts.”

The discussion will begin on October 21, 2008 at 2:30 pm at the Wynn Las Vegas where the Summit will be held. The session is particularly important for organizations, health plans and providers who are dealing with the costly impact of low back pain.

ABOUT PALLADIAN MUSCULAR SKELETAL HEALTH

Headquartered near Buffalo, N.Y., Palladian is a unique comprehensive, muscular skeletal service provider that integrates physical therapy, chiropractic and physical health and fitness with primary care to provide optimal outcomes for our health plan clients and their members. Palladian’s focus is on medical specialties that address muscular skeletal injuries in conjunction with ongoing wellness and care coordination. This integrated clinical approach facilitates optimum health outcomes which result in high levels of satisfaction and cost savings for members, providers and health plans.

ABOUT NASHO

NASHO was launched in January 2003 as a subsidiary association of the American Association of Preferred Provider Organizations (AAPPO) ( http://www.aappo.org/ ) to advance and evolve specialty healthcare delivery in the United States. Its mission is to enhance and promote the value proposition of specialty health organizations. To learn more about NASHO, visit http://www.nasho.org/ .

Palladian Muscular Skeletal Health

CONTACT: Bruce Bailey, +1-303-949-5056, for Palladian Muscular SkeletalHealth

Web site: http://www.nasho.org/http://www.aappo.org/

FDA Grants Orphan Drug Status to Reata’s RTA 402 for Treatment of Pancreatic Cancer

Reata Pharmaceuticals, Inc. announces that RTA 402 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. RTA 402 is currently being studied in a Phase 1/2 trial in patients with pancreatic cancer, and is also in Phase 2 development for chronic kidney disease.

“Pancreatic cancer is a devastating disease with few effective therapies,” said Warren Huff, CEO of Reata. “We are encouraged by the initial results with RTA 402 in pancreatic cancer, and are pleased that the FDA has recognized this potential by granting Orphan Drug status.”

FDA’s Orphan Drug Act was designed to encourage the development of products that demonstrate promise for the diagnosis, prevention and/or treatment of life-threatening or very serious conditions affecting 200,000 persons or less in the United States. Orphan drug designation provides an important economic incentive for the development of new products in the cancer field. U.S. orphan drug designation provides for seven years of market exclusivity, reduction in regulatory fees, and additional regulatory support for R&D initiatives.

About RTA 402

RTA 402 is an orally available, first-in-class Antioxidant Inflammation Modulator (AIM). RTA 402 and others AIMs work via a novel mechanism that promotes the resolution of inflammation and oxidative stress that underlie many intractable diseases, including cancer and renal/cardiovascular disease. Earlier this year, Phase 1 results with RTA 402 were presented at the Annual Meeting of the American Society of Clinical Oncology. The drug was shown to be well tolerated; to have single agent anti-cancer activity including multiple Objective Responses; to modulate target biological pathways including Nrf2, NF-kappaB, and STAT3; and to reduce levels of pro-inflammatory cytokines including TNF and VEGF. RTA 402 is currently in mid-stage clinical testing for pancreatic cancer and chronic kidney disease.

About Reata

Reata Pharmaceuticals, Inc. is a biopharmaceutical company focused on translating innovative science into breakthrough medicines for intractable diseases. The company’s lead program is in advanced clinical trials for chronic kidney disease and cancer. In parallel with its clinical development, Reata is advancing a breakthrough drug discovery platform based around the use of small molecule molecular chaperones to correct protein misfolding. Reata takes a new and different approach to biotechnology, managing its pipeline as a portfolio of opportunities that can be advanced on a single management and physical infrastructure, streamlining the route to human trials and approval. Founded in 2002, Reata is based in the Dallas area. For more information, visit www.reatapharma.com.

Akorn, Inc. Announces the Launch of Akten(TM) Gel 3.5%

Akorn, Inc. (NASDAQ: AKRX) today announced the commercial launch of Akten(TM) Gel 3.5%, a topical ocular anesthetic ophthalmic drug product. Akten(TM) represents the first FDA approved drug product indicated for use as an ocular anesthetic in four decades. Akten(TM) is the only approved ocular gel formulation that also contains the highest concentration of lidocaine. Akten(TM) has several unique features: it is preservative free, non toxic to the cornea, does not sting due to its physiological pH and can be stored at room temperature. Akten(TM) can be used as a local anesthetic indicated for ocular surface anesthesia during ophthalmologic procedures. Examples of these procedures include cataract/glaucoma surgery, intravitreal injections for retinal disorders, retina surgery, and miscellaneous ocular procedures both in hospital/clinics and office based practices.

The results of a phase III clinical trial for Akten(TM) have been published as a manuscript in a peer reviewed journal, Ophthalmic Surgery, Lasers & Imaging (OSLI); September/October 2008, “Lidocaine Hydrochloride Gel For Ocular Anesthesia: Results of a Prospective Randomized Study.” The study findings include safety, efficacy and tolerability of Akten(TM), and will be presented by Drs. B. Busbee, A. Alam and E. Reichel at the upcoming American Academy of Ophthalmology (AAO) meeting in Atlanta on November 8 and 9, 2008 at the Akorn booth #3421.

Akten(TM) will be marketed by Akorn’s 65 member sales team, who will detail ophthalmologists located in hospitals, surgery centers and private physician offices. An advertising awareness campaign is planned to launch Akten(TM). The initial marketing packet including an introduction letter, product details and benefits, package insert, an invitation to AAO and a copy of the OSLI clinical paper will be mailed to every ophthalmologist in the U.S. Akten(TM) will be prominently displayed monthly in EyeNet Magazine, the official journal of AAO. Akorn will also launch a detailed Akten(TM) website, www.akorn.com/akten, where physicians can become further educated on the product and order Akten(TM) online.

Arthur S. Przybyl, Akorn’s President and Chief Executive Officer stated, “I believe that Akten(TM) will become the standard of care whenever an ocular anesthetic is required. Akten(TM) represents a new horizon in ocular anesthesia. The benefits of Akten(TM) are important to consider whenever an ocular procedure is necessary.”

About Akorn, Inc.

Akorn, Inc. manufactures and markets sterile specialty pharmaceuticals. Akorn has manufacturing facilities located in Decatur, Illinois and Somerset, New Jersey and markets and distributes an extensive line of hospital and ophthalmic pharmaceuticals. Additional information is available at the Company’s website at www.akorn.com.

Materials in this press release may contain information that includes or is based upon forward-looking statements within the meaning of the Securities Litigation Reform Act of 1995. Forward-looking statements give our expectations or forecasts of future events. You can identify these statements by the fact that they do not relate strictly to historical or current facts. They use words such as “anticipate,””estimate,””expect,””project,””intend,””plan,””believe,” and other words and terms of similar meaning in connection with a discussion of future operating or financial performance. In particular, these include statements relating to future steps we may take, prospective products, future performance or results of current and anticipated products, sales efforts, expenses, the outcome of contingencies such as legal proceedings, and financial results.

Any or all of our forward-looking statements here or in other publications may turn out to be wrong. They can be affected by inaccurate assumptions or by known or unknown risks and uncertainties. Many such factors will be important in determining our actual future results. Consequently, no forward-looking statement can be guaranteed. Our actual results may vary materially, and there are not guarantees about the performance of our stock.

Any forward-looking statements represent our expectations or forecasts only as of the date they were made and should not be relied upon as representing our expectations or forecasts as of any subsequent date. We undertake no obligation to correct or update any forward-looking statements, whether as a result of new information, future events or otherwise, even if our expectations or forecasts change. You are advised, however, to consult any further disclosures we make on related subjects in our reports filed with the SEC. In particular, you should read the discussion in the section entitled “Cautionary Statement Regarding Forward-Looking Statements” in our most recent Annual Report on Form 10-K, as it may be updated in subsequent reports filed with the SEC. That discussion covers certain risks, uncertainties and possibly inaccurate assumptions that could cause our actual results to differ materially from expected and historical results. Other factors besides those listed there could also adversely affect our results.

L&M Healthcare Communications LLC Expands Client Services With Executive Team Expansion

MOUNTAINSIDE, N.J., Oct. 15 /PRNewswire/ — L&M Healthcare Communications LLC, an independent, full-service medical education company, today announced the hiring of Todd Weinstein as Vice President, Business Development.

Weinstein will leverage his experience in medical education and publishing as the head of Business Development. Prior to joining L&M, he served as Manager of Publication Sales at McMahon Publishing.

“Todd brings to L&M a wealth of experience in partnering with pharmaceutical companies to develop meaningful and relevant medical education platforms that support their brand and corporate needs,” said Adam Margolis, Partner at L&M Healthcare Communications.

“Todd’s proven record of forging solid client relationships through his experience in medical education and publications is a valuable addition to our team,” added Lenny LaManna, DPM, Partner at L&M Healthcare Communications. “Our experienced and highly strategic account service and scientific staff are well-positioned to actively partner with clients in the pre-launch, launch and post-launch phases of their products.”

The staff at L&M have more than 100 years of combined experience in healthcare communications in a variety of therapeutic areas including central nervous system diseases, anesthesiology, infectious disease, dermatologic conditions, wound healing, oncology, women’s health, gastroenterology, and urology. This experience, combined with L&M’s commitment to client service through the active involvement of senior leadership in all levels of client service and project management, and ensured compliance in this ever changing environment is what differentiates L&M from other agencies.

About L&M Healthcare Communications LLC

L&M Healthcare Communications LLC is an independent, full-service medical education company with offices in Mountainside, New Jersey and Milwaukee, Wisconsin. Core services include thought-leader/advocacy development, core launch educational materials, speakers’ bureau and publications.

L&M Healthcare Communications LLC

CONTACT: Adam Margolis, Partner, L&M Healthcare Communications,+1-908-588-9107, [email protected], http://www.lmhcare.com/

digiMedical Solutions, Inc. Implements Digital Prescription Software and Reauthorization Call Center Services for Dr. Matthew Teltser

digiMedical Solutions, Inc. (PINKSHEETS: DGMS) today announced that the Company has signed a contract with Dr. Matthew Teltser of the University Heart Institute in Pembroke Pines, Florida to implement the Company’s proprietary Microsoft .Net-based digital prescription handling software, digiRX, and digiReauth, the Company’s call center services, to support the reauthorization of prescriptions. Dr. Teltser, board certified with the American College of Cardiology and the American Board of Internal Medicine, received his medical degree from New Jersey Medical School in Newark, New Jersey.

digiMedical has operations in both Texas and Florida and, this year, has been actively expanding in Florida by signing a multitude of contracts with doctors and clinics to implement the Company’s proprietary digital prescription software and reauthorization call center services. Since launching those efforts, they have signed contracts with doctors in Florida to include: Drs. Griffin, Parker, Heitmann and Floreani of A Woman’s Place, Dr. Steven Bello and Dr. Thomas Magardino of Collier Otolaryngology, Dr. Richard Wilson, Drs. Angela Marshall, Wendy Humphrey and Betsy Brothers of Southwest Florida Women’s Group, P.A., Dr. Daniel Kaplan, Dr. Moorthy of Pain Management Center of Naples, Dr. Shardul Nanavati, founder of Advanced Gastroenterology, Drs. Romero, Tineo and Seibert of Oaktree Family Practice, Orthopedic Surgeon Dr. Howard Kapp of Anchor Health Centers, Drs. Santos-Ocampo, Axline and Spilker of the Collier Heart Group, Dr. John Landi, the Medical Director of Vanish Vein and Laser Center and Dr. Wey of the Neuroscience and Spine Associates in Naples, Florida, among others.

digiMedical’s Prescription Handling Software

digiMedical has built a suite of proprietary Microsoft .Net-based software to digitally and securely manage prescriptions in both doctor and clinic offices and in pharmacies. The software is compatible with most medical office software and is easy to install. With the software, the digital prescriptions are routed directly and securely from the physician’s office or clinic to the pharmacy. The digital pack of information also already contains pertinent patient information, allowing the pharmacy to pre-fill the prescription prior to the patient’s arrival at the pharmacy.

The Company’s digital prescription software suite meets HIPAA and DEA requirements and helps protect the pharmacist from errors caused by difficult-to-read handwritten prescriptions and the risk to the pharmacist of illegally duplicated prescriptions and fraudulent prescriptions. Additionally, digiMedical manages prescription refills for physicians’ offices and clinics through the Company’s digiReauth software and call center services. The suite of software includes digiRX, digiRxStream, digiReauth, digiRxComp, and digiAccounting.

Company Updates and Information

digiMedical’s software, which is currently in use in pharmacies in Naples and Ft. Meyers, Florida, and in Dallas, Texas, is now available for implementation nationwide in independent and chain pharmacies. If you are interested in learning more about digiMedical’s software, or implementing the Company’s proprietary technology in your pharmacy, please contact the Company at [email protected] or 1-877-450-8181.

To be added to digiMedical’s corporate e-mail list for shareholders and interested investors or to request additional information about the Company, please send an e-mail to [email protected].

About digiMedical Solutions, Inc.(TM)

digiMedical Solutions, Inc.(TM) (www.digimedical.com) is a pharmacy and medical technology company focused on developing next generation digital medical technology with an emphasis on digital prescriptions (d-Prescriptions) that will more closely align the doctor, pharmacist and patient. The Company’s digital prescription handling software captures and transmits prescriptions digitally from the physician’s office to the pharmacy, securely and in compliance with all DEA and HIPAA requirements. The suite of software includes digiRX, digiRxStream, digiReauth, digiRxComp, and digiAccounting.

Forward-Looking Statement

Statements included in this press release which are not historical in nature, are intended to be, and are hereby identified as “Forward-Looking Statements” for purposes of safe harbor provided by Section 21E of the Securities Exchange Act of 1934, as amended. Forward-Looking Statements may be identified by words including “anticipate,””await,””envision,””foresee,””aim at,””believe,””intends,””estimates” including without limitation, those relating to the company’s future business prospects, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the Forward-Looking Statements. Readers are directed to the company’s filings with the U.S. Securities and Exchange Commission for additional information and a presentation of the risks and uncertainties that may affect the company’s business and results of operations.

 Contact: digiMedical Solutions, Inc. Investor Relations [email protected] 214-722-3029  Sales: [email protected] 1-877-450-8181  

SOURCE: digiMedical Solutions, Inc.

Baxa Corporation Features PadLock(R) Set Saver at the ANCC National Magnet Conference(TM)

ENGLEWOOD, Colo., Oct. 15 /PRNewswire/ — Baxa Corporation is promoting its new PadLock Set Saver at the ANCC National Magnet Conference, October 15-17, in Salt Lake City. An aseptic IV administration set storage solution, PadLock provides a secure seal for the end of the administration set, preventing contamination when the set is not being used for infusion. Effective for multiple uses, the Set Saver attaches to an IV administration set and replaces the need for sterile, single-use caps. During the three-day exhibition, the Baxa sales team will demonstrate the new device at booth #613.

The ANCC, which sponsors the national conference, is the world’s largest and most prestigious nurse credentialing organization and gives exposure through this venue to more than 5500 highly qualified nurses. This conference supports excellence in nursing and promotes quality patient care. The innovative PadLock Set Saver is designed to foster best practice for aseptic IV administration set maintenance, preventing touch contamination and securing the IV line between drug administrations.

Baxa Corporation is a world leader in developing innovative technology for the safe handling, packaging and administration of fluid medications in hospital and alternate-care settings. Renowned for enhancing patient safety and improving processes within pharmacy settings. The PadLock Set Saver allows Baxa to bring its expertise and experience to the patient bedside.

About Magnet

The Magnet Recognition Program(R) was developed by the American Nurses Credentialing Center (ANCC) to recognize healthcare organizations that provide exceptional nursing care and uphold the tenets of professional nursing practice. Only 4% of U.S. hospitals have Magnet status. It is truly the “gold standard” for excellence in nursing. The program also provides a vehicle for disseminating best practices and successful strategies among healthcare organizations. Currently there are 265 Magnet organizations with hundreds more in the applications process. Regardless of a healthcare organizations size, setting, or location, achieving Magnet designation attracts and retains quality employees and ensures positive healthcare outcomes for consumers.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of medications. Key products include the PadLock(R) Set Saver, Rapid-Fill(TM) Automated Syringe Fillers, Exacta-Med(R) Oral Dispensers, MicroFuse(R) Syringe Infusers, Repeater(TM) Pharmacy Pumps, and Exacta-Mix(TM) and MicroMacro(TM) Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Austria, Belgium, Finland, France, Germany, Luxembourg, The Netherlands and Switzerland; and distribution partners worldwide. Further information is available at http://www.baxa.com/.

   Contact:    Marian Robinson, Vice President, Marketing   Baxa Corporation:  800.567.2292 ext. 2157 or 303.617.2157   Email:  [email protected]    Maggie Chamberlin Holben, APR   Absolutely Public Relations: 303.984.9801 or 303.669.3558   Email: [email protected]  

Baxa Corporation

CONTACT: Marian Robinson, Vice President, Marketing of Baxa Corporation,1-800-567-2292, ext. 2157, or +1-303-617-2157, [email protected]; orMaggie Chamberlin Holben, APR, Absolutely Public Relations, +1-303-984-9801,or +1-303-669-3558, [email protected], for Baxa Corporation

Web Site: http://www.baxa.com/

Study Finds Mannatech’s BounceBack(TM) Capsules Reduce Muscle Soreness*

Mannatech, Incorporated (NASDAQ:MTEX), a leading developer and provider of dietary supplements and skin care solutions, announced today that the results of a recent randomized, double-blind, placebo-controlled, crossover human study indicate that Mannatech’s BounceBack(TM) capsules significantly reduce muscle soreness after overexertion.*

These results complement the already established benefits of BounceBack(TM) capsules in reducing soreness and stiffness from physical activity, and supporting optimal joint and cartilage health.*

This human clinical study, presented at the 2008 International Society of Sports Nutrition Conference and Expo, was published on Sept. 17 in the Journal of the International Society of Sports Nutrition. It was stringently designed and conducted “to evaluate the ability of BounceBack(TM) capsules to reduce the signs and symptoms of DOMS (delayed onset muscle soreness) and increase the rate of muscle recovery following eccentric exercise.”*

“The design of this study achieves the gold standard of a randomized, blinded and well-controlled, product-specific human study,” said Dr. Robert A. Sinnott, senior vice president and chief science officer at Mannatech. “The wellness industry has come a long way since the passage of the Dietary Supplement Health and Education Act in 1994. While the burden of scientific proof has become more stringent, these changes are for the better. Consumers are insisting on access to high quality products with proven performance. This is just one of the ways that Mannatech is working to open new frontiers in the area of nutritional science.”

The results of this pilot study demonstrate “statistically significant differences in favor of BounceBack(TM) capsules for pain, tenderness and the amount of energy expended.”* Specifically, researchers concluded that BounceBack(TM) capsules “resulted in a significant reduction in standardized measures of pain and tenderness post-eccentric exercise, even after engaging in significantly more activity in the two-day period prior to the exercise protocol.”*

The research was conducted by Medicus Research LLC, a contract research organization based in Northridge, Calif. To view the study findings, please visit http://www.jissn.com/content/pdf/1550-2783-5-S1-P24.pdf or http://www.jissn.com/content/5/S1/P24.

The full scientific manuscript, including statistical analysis, has now been submitted for publication. Follow-on studies of this product are being planned to further explore beneficial structure-function activities.

*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

About Mannatech

Mannatech, Incorporated, is a global wellness solutions provider of innovative, high quality, proprietary dietary supplements, skin care products, and weight and fitness products sold through independent associates and members located in the United States and the international markets of Canada, Australia, the United Kingdom, Japan, New Zealand, the Republic of Korea, Taiwan, Denmark, Germany, South Africa and is scheduled to open in Singapore during the fourth quarter of 2008. For more information please visit www.mannatech.com or www.allaboutmannatech.com.

Please Note: This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as “intend” or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech’s objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the United States Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech’s inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that the expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K and Quarterly Report on Form 10-Q, and other filings filed with the United States Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.

Delcath Systems Appoints Eamonn Hobbs to Board of Directors

Delcath Systems, Inc. (NASDAQ: DCTH) today announced the appointment of Mr. Eamonn Hobbs to Delcath’s Board of Directors. Mr. Hobbs is President and Chief Executive Officer of AngioDynamics, Inc. (NASDAQ: ANGO), a leading medical device company specializing in the development and sales of medical technology serving the needs of interventional oncologists and vascular interventionalists.

Mr. Hobbs, a Co-Founder of AngioDynamics, built his company into a leading medical technology company with an international market presence with a highly diverse product line. Throughout his tenure at AngioDynamics, Mr. Hobbs has led the Company’s efforts in marketing, strategic planning, product development, and general management. In 2004, AngioDynamics was spun off from E-Z-EM, Inc., a company focusing on diagnostic radiology and gastrointestinal technologies, and of which Mr. Hobbs was the Senior Vice-President since 1988. Before his involvement with these companies, Mr. Hobbs was the Director of Marketing and Product Development at NAMIC, Founder, President and CEO of Hobbs Medical, Inc., and a Product Development Engineer at Cook Incorporated.

On joining Delcath’s Board of Directors, Mr. Hobbs commented, “This is an exciting time for Delcath, and I am pleased to be joining the Board during this period of growth and expansion. I am impressed with the Company’s technology, the promising results of the Phase III Trial, and the excellent management team. I believe that the Company is poised for significantly more growth and success in the emerging market of minimally invasive cancer treatments, and I look forward to leveraging my extensive experience to aid that successful growth.”

Mr. Hobbs continues to be highly active in the field of interventional radiology, where he has been named an Honorary Fellow of the Society of Interventional Radiology (“SIR”), is on the SIR Strategic Planning Committee, and is a Member of the Society of Cardiovascular and Interventional Radiology. Mr. Hobbs is a frequent presenter at industry and medical conferences, and sits on the Board of Directors of the Medical Device Manufacturers Association, the Society of Interventional Radiology Foundation, and the American College of Phlebology Foundation.

Commenting on today’s announcement, Richard L. Taney, President and Chief Executive Officer of Delcath, stated, “We are delighted to have Eamonn join the Board of Directors of Delcath. His successful leadership of AngioDynamics, his experience within the medical device industry and his involvement in a number of influential medical organizations make him a welcome addition to our Board of Directors. I look forward to working with Mr. Hobbs and the entire Board while we continue our progress in completing our clinical trials.”

About Delcath Systems, Inc.

Delcath Systems, Inc. is a medical technology company specializing in cancer treatment. The Company has developed a proprietary, patented system which will improve the efficacy of cancer treatment while reducing the considerable, systemic side-effects of chemotherapy. Delcath’s novel drug delivery platform is capable of delivering anti-cancer drugs at very high doses to a specific organ or region of the body while preventing these high doses of drug from entering the patient’s bloodstream. The Company is currently enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. The Company’s intellectual property portfolio consists of twenty-eight patents on a worldwide basis including the U.S., Europe, Asia and Canada. For more information, please visit the Company’s website at www.delcath.com.

The Private Securities Litigation Reform Act of 1995 provides a safe harbor for forward-looking statements made by the Company or on its behalf. This news release contains forward-looking statements, which are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to our ability to successfully complete Phase III clinical trials and secure regulatory approval of our current or future drug-delivery system and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.

 Contact: Company Contact: Delcath Systems, Inc. Richard L. Taney (212) 489-2100 Email Contact  Investor Relations Contact: Strategic Growth International, Inc. Richard E. Cooper (212) 838-1444 Email Contact  Public Relations Contact: Rubenstein Associates, Inc. Robin Wagge (212) 843-8006 Email Contact

SOURCE: Delcath Systems

Dr. Mel Spigelman, Director of Synergy Pharmaceuticals, Appointed President and CEO of Global Alliance for TB Drug Development

Synergy Pharmaceuticals, Inc. (OTC BB:SGYP.OB SGYP News) is pleased to congratulate Melvin K. Spigelman, M.D., a director of Synergy Pharmaceuticals, on his recent appointment as President and CEO of the Global Alliance for TB Drug Development (TB Alliance), a not-for-profit product development partnership seeking to develop new drugs to treat tuberculosis.

Dr. Spigelman has been a director of Synergy Pharmaceuticals since August, 2008. Dr. Spigelman previously served as Director of Research and Development for the Global Alliance for TB Drug Development. Before joining the Global Alliance for TB Drug Development, Dr. Spigelman was President of Hudson-Douglas Ltd, a consulting company, from June 2001 to June 2003. From 2000 to 2001, Dr. Spigelman served as a Vice President, Global Clinical Centers at Knoll Pharmaceuticals, a pharmaceutical unit of BASF Pharma. He received a B.A. in engineering from Brown University and an M.D. from The Mount Sinai School of Medicine; and is board certified in internal medicine, medical oncology and preventive medicine.

“Dr. Mel Spigelman’s appointment as President and CEO of the TB Alliance further testifies to his unique mix of pharmaceutical and management expertise, combining broad experience in research and development, commercialization, academic oversight and global public health,” said Gary S. Jacob, President and Acting CEO of Synergy. “Mel’s association with Synergy has only been for a few months, yet he has already made a considerable impact on the clinical development of our drug SP-304 to treat chronic constipation and IBS-C.”

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases, and is a subsidiary of Callisto Pharmaceuticals, Inc. (OTC BB: CLSP). Synergy’s proprietary drug SP-304 began clinical development in June 2008 for gastro-intestinal disorders. SP-304 is currently finishing a Phase I clinical trial in volunteers to treat chronic constipation and IBS-C. SP-304 is a synthetic analog of the human gastrointestinal hormone uroguanylin, and acts by activating the guanylate cyclase C (GC-C) receptor on epithelial cells of the colon. More information is available at http://www.synergybio.net.

iinnLight’s Molecular Massage(TM) Makes Strong Debut at Spa Expo

There is now a stress-relieving treatment Americans can obtain to quickly alleviate stress and gain renewed energy. At a recent spa industry expo in New York, iinnLight Technologies, Inc., the emerging leader in optimizing light to transform and energize lives, debuted its patented Molecular Massage(TM), a hands-free cellular tissue massage using safe and non-invasive LED light therapy. While at the bustling expo, 144 participants experienced a Molecular Massage over a two-day period and 90% reported experiencing profound stress relief and feeling a deep state of relaxation and wellbeing that lasted long after their session.

“We were delighted with the feedback and positive testimonials participants gave for the Molecular Massage,” said Kathleen Buchanan, CEO and founder of iinnLight. “People came to their 15- and 30-minute sessions visibly stressed and hurried, and left bewildered at how relaxed and rejuvenated they felt afterwards. Spas have an extraordinary opportunity right now to offer a stress-relieving treatment during a time when people are extremely distressed about what’s happening in the economy coupled with the pressures of the upcoming holiday season.”

According to a September 2008 survey by the American Psychological Association, Americans are experiencing more stress this fall than they were in the spring. iinnLight’s Molecular Massage is the ideal treatment that spas can offer to meet the growing needs of consumers looking for affordable relief from everyday anxieties. The Molecular Massage provides an immediate gratification – people look and feel better, and it can greatly enhance the effects of other spa treatments.

“We gave serious consideration to incorporating the Molecular Massage after experiencing its benefits first hand,” said Tony Margerum and Tana Diaz-Margerum, co-owners of The Journey Spa and Wellness Center, Orange, Calif. “We currently offer Molecular Massages in packages that are very popular to our clients wanting stress or pain relief, or facial improvements.”

How it Works

The iinnLight Pro(TM) delivers the patented Molecular Massage and emanates three specific wavelengths of modulated light during each 30-minute session. The light, typically applied directly over the face, is absorbed into the body’s tissue then translated into energy which stimulates cellular growth, repair and regeneration of the body. iinnLight Pro specifically stimulates the immune system to promote the most natural form of healthy aging.

No larger than a standard floor lamp, the mobile delivery system enables spa employees to easily maneuver the iinnLight Pro to accommodate treatments in different rooms. iinnLight Pro does not require a licensed technician to operate; the employee simply presses a button to start the light therapy and it automatically turns off after 30 minutes. This gives the opportunity to offer clients a unique, safe and non-invasive wellness and anti-aging solution with no increase in labor. In addition to feeling revitalized, spa guests who experience iinnLight’s Molecular Massage report seeing a visible reduction in the appearance of fine lines and wrinkles. For testimonials, visit http://www.iinnlighttherapy.com/testimonials/testimonials.php.

Pricing and Availability

iinnLight Pro is currently available for sale to destination and resort spas, day spas, and hotels that are focused on providing the latest wellness and anti-aging solutions for their guests. Attractive leasing options are available. Contact iinnLight Technologies for sales and trial offer information at 949-340-1695.

About iinnLight

iinnLight provides patented energizing light therapy technology that enables spas to seamlessly increase profits and dramatically capitalize on the wellness revolution with the world’s first Molecular Massage(TM). iinnLight’s safe and non-invasive light treatments pave the way to the benefits most important to today’s busy individual: stress relief, beauty, restfulness and healthy aging. iinnLight is headquartered in Laguna Beach, Calif. For more information, visit http://www.iinnlighttherapy.com or call 949-340-1695. Note to editors: A photo of the iinnLight Pro can be downloaded at http://www.iinnlighttherapy.com/media. iinnLight, iinnLight Pro and Molecular Massage are trademarks of iinnLight Technologies, Inc.

Shark Blood Could Be Potential Cancer Treatment

According to Australian scientists, antibodies found in shark blood could potentially be used to fight cancer.

Sharks have antibodies – molecules that fight disease – that are exceptionally adaptable, and tough. Researchers believe they can harness these attributes and use them to slow the spread of cancer.

They hope the idea can lead to a new line of drug treatments.

The team of researchers found that shark antibodies are capable of withstanding very acidic or alkaline conditions, and are resistant to high temperatures. This makes them capable of surviving in the human body, which is a necessity in creating a cancer fighting pill.

According to Professor Mick Foley of Melbourne’s La Trobe University, the shark molecules are able to attach themselves to cancer cells, and are able to stop the cancer from spreading.

“The cells actually grow less than where we don’t add a shark antibody or we add a completely irrelevant shark antibody,” Foley said.

“So this indicates the shark antibody that we have is binding to those cancer cells and for some reason causing them to grow more slowly and perhaps even killing them.”

The researchers chose sharks for the study because of their robust immune systems, and because of the similarities between the human immune system and the shark immune system.

Researchers already have evidence that the antibodies can slow the spread of breast cancer, but they are also hoping to use the antibodies to fight other diseases such as malaria and rheumatoid arthritis.

On the Net:

SwiftMD Physicians and Patients to Securely Share Medical Information Through a Customized Electronic Medical Record

NEW YORK, Oct. 15 /PRNewswire/ — SwiftMD (http://www.swiftmd.com/), a Web- and phone-based medical diagnosis service, will enable its physicians and patients to share medical information online through a secure, customized, HIPAA-compliant portal. SwiftMD, whose physicians provide patient consultations via phone or bi-directional Internet video and audio, will use SSIMED EMRge Electronic Health Records, developed by SSIMED.

With SSIMED EMRge, the SwiftMD physicians can view members’ current personal health information, including medications, medical history, lab test results and past appointments prior to and during each “virtual visit.” After the encounter, the updated information from the Electronic Health Record (EHR/EMR) is copied into SwiftMD’s secure member portal, where the member can review the physician’s notes. SwiftMD’s members have access to their personal online record 24/7, anywhere in the world.

“The SwiftMD EMR is a powerful tool that enables our physicians to provide better care to members, because both physicians and members are able to access and view the most up-to-date personal health information,” commented Elliot Justin, M.D., founder of SwiftMD and a board-certified emergency medicine physician. “Strengthened by SSIMED’s expansive clinical knowledge engine and intelligent prompting, the EMR supports SwiftMD physicians in considering the differential diagnosis for medical conditions before concluding a consultation and ordering prescriptions. With this EMR, SwiftMD can provide superior and faster care than patients can receive in most ERs, urgent care centers and primary care offices.”

The SSIMED EMRge product allows physicians to build stronger, more collaborative personal relationships with patients. Using EMRge, SwiftMD physicians have access to the latest research, literature and textbooks. With the click of a button, the physician can share relevant information with the SwiftMD member, saving them the time of doing their own independent research.

When patients have existing prescriptions recorded within their Electronic Health Record, SwiftMD physicians can accurately determine correct medications to treat new conditions. SSIMED EMRge lists all drug reactions, black box warnings and potential allergic reactions and prompts the physician to consider other medications. This tool helps SwiftMD physicians avoid potential medication errors. “Medication errors in the healthcare system today represent the number one cause of patient harm,” noted Dr. Justin. “SSIMED automatically alerts SwiftMD physicians of any potential drug interactions and avoids medication errors.”

“We are proud to be working with SwiftMD, the first telemedicine provider to empower its physicians with SSIMED’s robust Electronic Health Record solution. With EMRge’s integrated tools and built-in intelligence, the SwiftMD physician can utilize the capabilities of the EMR to support the diagnosis and treatment options available,” said Daniel McMahon, CEO of SSIMED.

About SSIMED, LLC

SSIMED’s software and services currently provide thousands of physicians with the flexible tools needed to manage today’s complex medical practices. Offering practice management software, Electronic Health Records (EHR/EMR), billing services, revenue cycle management services and business intelligence, SSIMED consistently provides its clients with state-of-the-art solutions and world-class service. For more information about SSIMED visit http://www.ssimed.com/ or call 1.800.276.6992.

About SwiftMD

SwiftMD is the first telemedicine service of its kind in the U.S. to offer subscribing consumers anytime, anywhere access to board-certified, emergency medicine physicians. Through SwiftMD, members can consult with a doctor via the telephone or the Internet to obtain a diagnosis, prescription or referrals to other types of care. SwiftMD’s Personal Health Record (PHR) allows members to store, update and manage their personal health information. Committed to expanding consumer choice and control in securing quality healthcare, SwiftMD offers its services to individuals, employers, health plans and government agencies. Employers who include SwiftMD memberships in their benefits plans can save thousands of dollars annually while ensuring employees receive superior care. For more information, visit http://www.swiftmd.com/.

   Media Contact:   Christopher Capot   KNB Communications   212-505-2441   [email protected]  

SwiftMD

CONTACT: Christopher Capot, of KNB Communications, +1-212-505-2441,[email protected]

Web Site: http://www.ssimed.com/http://www.swiftmd.com/

Sharp Community Medical Group Rolls Out SCMG Connect, an Electronic Health Record and Practice Management System Powered By Allscripts

SAN DIEGO, Oct. 15 /PRNewswire/ — Sharp Community Medical Group (SCMG) has become the first IPA in the nation to roll out an innovative implementation of Allscripts Enterprise Electronic Health Record (EHR) and Practice Management (PM) solution. The system, called SCMG Connect, will use a unique architecture to automate and connect clinical and administrative processes for SCMG’s 700 physician members and affiliates to better serve the network’s more than 156,000 managed care patients.

According to John Jenrette, MD, CEO of SCMG, SCMG Connect generates a single medical record for each patient even if seen at different practices by primary and specialist physicians. This secure and confidential common patient record becomes accessible in real time to all SCMG network-affiliated physicians and includes doctors’ notes, as well as radiology and laboratory results and medications.

“SCMG Connect enables SCMG’s physicians to instantly access patient information when and where they need it — in their practices, at the hospital or while on-call at home,” said Jenrette. “The web-based solution speeds and automates everyday clinical tasks such as prescribing and refilling medications, ordering and viewing tests, and documenting care. This dramatically enhances the portability of patient records, while maintaining the highest levels of confidentiality.”

Jenrette emphasized that the portability and confidentiality built into the Allscripts Electronic Health Record is consistent with the California Regional Health Information Organization’s collaborative effort to incrementally build the structure and capabilities necessary for a secure statewide health information exchange system that enables California’s health care providers and patients to access vital medical information at the time and place it is needed.

Additionally, offices that adopt SCMG Connect will use Allscripts practice management software that utilizes sophisticated scheduling and financial management tools in a single package with advanced functionality such as rule-based appointment scheduling, multi-resource and recurring appointment features, referral and eligibility indicators, and appointment and claims management.

“Our physicians are dedicated to delivering the best possible patient care as efficiently as possible, and Allscripts has proven they can deliver the tools to help physicians do just that,” said Christopher McGlone, Chief Operating Officer of SCMG. “We’re excited to be able to offer this integrated solution to our physicians, many of them in smaller practices who may feel they can’t afford a full Electronic Health Record system but who want the benefits of patient safety, efficiency and connectivity to the entire SCMG network of physicians.”

Allscripts Chief Executive Officer Glen Tullman commented, “We are proud to have SCMG, the largest IPA in the San Diego community, launch Enterprise Electronic Health Record and become part of a growing list of IPAs that are rolling out our solutions to help their physicians and other caregivers deliver higher quality care in a more cost effective fashion.”

About Sharp Community Medical Group

Sharp Community Medical Group is an association of private practice primary care physicians and specialists who practice in their own private offices located conveniently throughout San Diego County. The Sharp Community Medical Group network includes over 700 primary care and specialty physicians who currently provide care to more than 156,000 managed care patients. For additional information visit SCMG online at http://www.scmg.org/.

About Allscripts

Allscripts uses innovation technology to bring health to healthcare. More than 150,000 physicians, 700 hospitals and nearly 7,000 post-acute and homecare organizations utilize Allscripts to improve the health of their patients and their bottom line. The company’s award-winning solutions include electronic health record, electronic prescribing, revenue cycle management, practice management, document management, medication services, hospital care management, emergency department information systems and homecare automation. Allscripts is the brand name of Allscripts-Misys Healthcare Solutions, Inc. To learn more, visit http://www.allscripts.com/.

This news release may contain forward-looking statements within the meaning of the federal securities laws. Statements regarding future events, developments, the Company’s future performance, as well as management’s expectations, beliefs, intentions, plans, estimates or projections relating to the future are forward-looking statements within the meaning of these laws. These forward-looking statements are subject to a number of risks and uncertainties, some of which are outlined below. As a result, actual results may vary materially from those anticipated by the forward-looking statements. Among the important factors that could cause actual results to differ materially from those indicated by such forward-looking statements are: the volume and timing of systems sales and installations; length of sales cycles and the installation process; the possibility that products will not achieve or sustain market acceptance; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; competitive pressures including product offerings, pricing and promotional activities; our ability to establish and maintain strategic relationships; undetected errors or similar problems in our software products; compliance with existing laws, regulations and industry initiatives and future changes in laws or regulations in the healthcare industry; possible regulation of the Company’s software by the U.S. Food and Drug Administration; the possibility of product-related liabilities; our ability to attract and retain qualified personnel; our ability to identify and complete acquisitions, manage our growth and integrate acquisitions; the ability to recognize the benefits of the merger with Misys Healthcare Systems, LLC (“MHS”); the integration of MHS with the Company and the possible disruption of current plans and operations as a result thereof; maintaining our intellectual property rights and litigation involving intellectual property rights; risks related to third-party suppliers; our ability to obtain, use or successfully integrate third-party licensed technology; breach of our security by third parties; and the risk factors detailed from time to time in our reports filed with the Securities and Exchange Commission, including our 2007 Annual Report on Form 10-K available through the Web site maintained by the Securities and Exchange Commission at http://www.sec.gov/. The Company undertakes no obligation to update publicly any forward-looking statement, whether as a result of new information, future events or otherwise.

Sharp Community Medical Group

CONTACT: Dennis Ellman, +1-858-453-9600, for Sharp Community MedicalGroup

Web site: http://www.scmg.org/

Cellulite in 3D, Presentation at American Society of Plastic Surgeons Next Month

MERRIMACK, N.H., Oct. 15 /PRNewswire/ — Internationally recognized San Francisco plastic surgeon, Michael Kulick, MD, has developed a 3D imaging validation method for quantitatively measuring changes in cellulite. Dr. Kulick has been named one of the key investigators involved in an IRB-approved, multi-center, prospective, randomized clinical study to investigate the efficacy of the SmoothShapes(R) system(1). Dr. Kulick began his study in May and will present findings at the Chicago American Society of Plastic Surgeons meeting on November 2-4, 2008. More than 85 percent of women will develop cellulite at some point in their life and it can’t be controlled or eliminated through diet or exercise.

With an industry-leading practice of more than two decades, Dr. Kulick is using a validation method in his SmoothShapes study that is significantly more data oriented than traditional photography. He acquires specialized images with a 3D imaging camera for assessment of volumetric changes. The groundbreaking validation method documents improvement in cellulite in three dimensions.

“I chose to work with Eleme Medical on this study because the company is focused on body shaping technologies and dedicated to investigating the understanding of the tissue components responsible for cellulite and fat. The basic science behind the SmoothShapes technology is sound and my patients are very concerned about the irregularities of their skin contour and they are looking for a reliable way to smooth their skin’s surface,” commented Dr. Kulick.

Using the 3D system to validate results of the study will allow new data points for documenting improvement in the appearance of cellulite. “This system is designed to provide reproducible 3D photographs and measure change in the volume between two surfaces. Therefore, if a positive change is observed after treatment, we should be able to tell what kind of volume change provided these results,” explained Dr. Kulick. He adds, “The imaging process will also allow my study to track results over time.”

Perfected after seven years of development, the SmoothShapes device uses a proprietary technology called Photomology(R) which can ultimately result in longer-lasting cellulite improvement and the appearance of tighter, smoother skin. Thermal and non-destructive, Photomology’s unique mechanism of action combines dynamic laser and light energy with mechanical massage and vacuum to specifically impact the tissue components responsible for the appearance of cellulite. Collagen is regenerated, circulation is improved and metabolic processes are restored. The result is tighter and smoother looking skin.

Although the original SmoothShapes device gained FDA market clearance in July 2006, Eleme Medical pursued market preference studies at 16 test centers around the world before launching the device commercially in April of 2008. “At Eleme Medical we are serious about the science of cellulite for SmoothShapes system and dedicated to providing market leading technology in all areas of body shaping,” said Nancy M. Briefs, President and Chief Executive Officer of Eleme Medical, Inc. “Dr. Kulick’s study is providing valuable understanding of cellulite and subcutaneous fat and will add to the other validation methods we have used to prove SmoothShapes consistent results in the improvement of cellulite. In addition to using traditional photography to document cellulite improvement, and now Dr. Kulick’s 3D work, we also have studies with both MRI and ultrasound validations,” said Ms. Briefs.

About Eleme Medical:

Eleme Medical, headquartered in Merrimack, N.H., is dedicated to providing market leading technology in all areas of body shaping. SmoothShapes(R) system with Photomology(R) is the company’s preeminent product to launch. SmoothShapes is a medical device with FDA clearance to market for temporary reduction in the appearance of cellulite. The Company’s name, when spoken phonetically, suggests “lasers, medicine and aesthetics.” For more information, or to arrange an interview with Dr. Kulick about SmoothShapes and his study, please contact Behrman Communications at 212.986.7000.

(1) SmoothShapes has been demonstrated effective in improving the appearance of cellulite as been reported at the 28th Annual Meeting of the American Society for Laser Medicine and Surgery in Kissimmee, FL in April 2008 (K.Khatri et al, Effectiveness of SmoothShapes(R) Cellulite Treatment as Monitored with High-Frequency Ultrasound Imaging, Lasers Surg Med, 2008, S20: 13; M.Pankratov et al, Photomology(R) — Some Experimental Evidence in Support of Postulated Mechanism of Action, Lasers Surg Med, 2008, S28: 164).

Eleme Medical

CONTACT: Behrman Communications, +1-212-986-7000

Gilbert Hospital Only Hospital in Arizona to Successfully Report Required Data

GILBERT, Ariz., Oct. 14 /PRNewswire-USNewswire/ — According to the Department of Health Services, Gilbert Hospital, located in Gilbert Arizona, was the first and only hospital of 88 in Arizona to successfully submit the required Arizona Hospital Discharge Data Report, a mandatory state filing. The report is required by the Arizona Department of Health Services to be submitted twice annually. However, changes to the 2008 report created a complex issue for hospitals wherein the report format had to be re-written from scratch. It is up to each hospital to compile, process, write and distribute this data. Then, the report is submitted to the State agency.

This specific undertaking was spearheaded by Michele Cianfrani, Gilbert Hospital’s Director of Information Services. “We knew we had a tough task ahead of us when DHS advised us of the format changes,” admitted Ms. Cianfrani. “A strong team and many dedicated hours later, our report made it through as the only successful submittal in Arizona. It is a great compliment to the entire team,” she continued.

The AZ Hospital Discharge Data Report is audited and reviewed by ADHS and required to be in compliance with state statutes. Each hospital is required to submit the Discharge Data Report, which provides information about finding the average price of a procedure at each particular hospital, comparing prices between the hospitals and links to hospital financial assistance and payment policies. “By having this report online, it gives patients the ability to research and compare prices,” said Cianfrani, who has been IT Director at Gilbert Hospital since its inception. “Building this new format from scratch and then being the only successful hospital in Arizona to provide the reports speaks volumes for what Gilbert Hospital stands for.”

The Arizona Hospital Discharge Data Report is part of a state-wide reporting structure required by all hospitals to be submitted to the Arizona Department of Health Services. For information regarding these reports, please visit: http://www.azdhs.gov/ or http://azhospitalchoice.org/

About Gilbert Hospital

Located at 5656 S. Power Rd., a half mile south of Ray Rd., Gilbert Hospital (http://www.gilberter.com/) is licensed as an acute-care general hospital with 24/7 services including emergency; expanded in-patient including ICU; diagnostic imaging; pharmacy; laboratory; and surgery services. Designated as a Level II trauma center, Gilbert Hospital provides health care services to the communities located throughout the east and southeast valley. Initial evaluations of all patients by a Board certified emergency physician begins within 31 minutes of arrival.

For more information about this release or about Gilbert Hospital, contact: Mr. Drew Markell, 480-840-3837 or 480-529-8259

Gilbert Hospital

CONTACT: Drew Markell of Gilbert Hospital, +1-480-840-3837,+1-480-529-8259

Web Site: http://azhospitalchoice.org/

Dr. Daniel Ronel Offers Holistic Plastic Surgery

SANTA FE, N.M., Oct. 14 /PRNewswire/ — Over the last two decades, incredible advancements in the field of plastic and reconstructive surgery have led to significant improvements in patient outcomes. Year after year, less invasive procedures that accomplish better and better results have been developed. Patients undergo less time on the operating table and have a shorter recovery time. For one Ivy-League trained plastic surgeon, these advances are taken a step further by incorporating elements of alternative medical therapies into the traditional standard of care.

Dr. Daniel Ronel is a Board-Certified plastic surgeon in Santa Fe, NM. He explains that incorporating alternative therapies and modalities into his practice has made a significant improvement in his patient results, even after the less-invasive, modern techniques he uses. “We began to look at the biggest concerns our patients had when it came to their procedures, and the number one goal was a decreased amount of downtime after surgery. By implementing a more comprehensive approach to the patients we see, we are able to help them achieve their goal. Then we took it a step further.” Dr. Ronel uses methods such as acupuncture, aroma-guided imagery, nutritional supplementation, and even psychotherapy, depending on the patient and their procedure, to achieve what he calls ‘The New Plastic Surgery.’ Dr. Ronel explains, “The decision to include a holistic approach as an adjunct to the standard procedures has really improved the results the patient experiences. I was skeptical at first, but now I am convinced.”

For Una Medina of Santa Fe, the surgery was only part of the plan to improve her self-image. “Dr. Ronel’s approach leaves nothing out, which meant that I was afforded the greatest success when it came to my surgery. I really believe that bringing in all the extra elements; the acupuncture, the imagery, the nutrition, all of it played a very significant role in my body’s ability to heal itself that much more quickly, and I believe that was the determining factor in my success.”

Dr. Ronel explains that plastic surgery patients today are far more focused on the event of their procedure as a whole than they were just five or ten years ago. “Nowadays, when a patient comes in for a procedure, they really look at the change they will undergo as a process; essentially, a life- changing event. This gives me the chance to inspire healthier lifestyle choices in my patients because they get to experience the transformation from the inside out, not just through the difference in appearance. I see this as a fantastic opportunity for me to address issues such as nutrition, stress management, smoking cessation, etc that are sometimes even more important than the physical changes of the surgery.” For Una Medina, the ‘whole being’ approach Dr. Ronel employs was far more enjoyable because, “I was able to have a direct and positive impact on my surgery…this made me feel more in control and empowered.”

DR. DANIEL RONEL is a board-certified plastic surgeon with offices in Santa Fe and Albuquerque, NM. Educated and trained at Princeton, Penn, Columbia, Cornell, and Harvard, he is the only surgeon in the US who is board certified in both plastic surgery and pediatrics. Dr. Ronel was named one of America’s Top Plastic Surgeons by the Consumer’s Research Council of America. Because of his combined expertise in pediatrics and plastic surgery, Dr. Ronel is one of 13 national experts selected by Allergan to sit on the Breast Implant Research Team. Additionally, Dr. Ronel is a member of the Radiesse Medical Education Facility, a group composed of approximately 120 physicians from across the United States who are experts in the field of injectable fillers. He was voted Albuquerque’s Plastic Surgeon of the Year in 2007 by readers of The Herald, and was named one of Albuquerque’s 2007 Top Docs by Albuquerque, the Magazine.

Dr. Daniel Ronel

CONTACT: HOLMES WORLD MEDIA INC., +1-806-368-9194, for Dr. Daniel Ronel

Web site: http://www.danielronelmd.com/

Tenet Healthcare to Outsource Materials Management and Procurement to Broadlane

Tenet Healthcare Corporation (NYSE: THC) today announced that the subsidiaries operating its 52 hospitals have outsourced their materials management and procurement functions to Broadlane, the nation’s largest and fastest growing provider of hospital supply chain services. Beginning Jan. 1, 2009, and continuing through early 2010, Tenet’s approximately 200 materials management and procurement employees will become Broadlane employees.

In September, Tenet signed a seven-year agreement with Broadlane to manage its approximate $1.5 billion in annual spend.

“Since our relationship with Broadlane began in 1999, we have seen tremendous savings in supply spend at all of our hospitals,” said Stephen L. Newman, M.D., chief operating officer, Tenet Healthcare Corporation. “With this new outsourcing arrangement, we anticipate realizing even greater savings.”

Tenet has extended and expanded its relationship with Broadlane with the following goals and expectations:

— Accelerate the pace and breadth of cost reduction initiatives;

— Reduce variation in practices and improve operational performance;

— Improve inventory performance and cash flow; and

— Provide exemplary customer service.

Tenet Healthcare Corporation, through its subsidiaries, owns and operates acute care hospitals and related ancillary health care businesses, which include ambulatory surgery centers and diagnostic imaging centers. Tenet is committed to providing high quality care to patients in the communities we serve. Tenet can be found on the World Wide Web at www.tenethealth.com.

Some of the statements in this release may constitute forward-looking statements. Such statements are based on our current expectations and could be affected by numerous factors and are subject to various risks and uncertainties discussed in our filings with the Securities and Exchange Commission, including our annual report on Form 10-K for the year ended Dec. 31, 2007, our quarterly reports on Form 10-Q and periodic reports on Form 8-K. Do not rely on any forward-looking statement, as we cannot predict or control many of the factors that ultimately may affect our ability to achieve the results estimated. We make no promise to update any forward-looking statement, whether as a result of changes in underlying factors, new information, future events or otherwise.

Web Site Launched To Report Bullying

Six schools in Utah have launched a new Web site that gives students a platform to anonymously report information about drugs, theft, bullying and other forms of harassment.

Justin Bergener, a student at Brigham Young University, created the SchoolTipLine Web site.  He hopes that students who might be otherwise too intimidated or shy to speak up will be willing to anonymously post their complaints online.

“There really is this culture and code of silence that’s particularly prevalent in middle schools and high schools,” Bergener told the Associated Press on Monday.

“It allows students to have an outlet and avenue to report things they might otherwise not have reported,” Rosanna Ungerman, principal of Provo’s Dixon Middle School, told the AP, adding that some students may not want to be seen talking to school authorities.  

So far, nearly 50 schools in other states are also using the Web site. The six Utah schools include elementary, middle and high schools.

Students wishing to report an incident on SchoolTipLine must first send an e-mail or text message tip to school administrators, said Bergener. Some schools require students to create a logon and password before sending a tip, however the students remain anonymous. In most cases a tip can be sent without students having to provide any personal information.  

“They’d rather have 10 good ones and one false one than none at all,” Bergener told the AP.

Bergener said his Web site simply acts as a third party that passes tips along. The site, which has participating schools in California, Arizona, Texas and Washington, does not read or reply to the tips, but if a tip goes unread for a day or so, it will remind the school that it’s there.

Some parents have even started reporting incidents to the site, according to  Lehi Junior High’s assistant principal Judy Runolfson.

“There’s a greater awareness that it’s a situation that needs to be looked into right away because we know it can lead from something that’s not that bad to something much worse,” she told the AP.

On the Net:

Independence Blue Cross Members Have Broadened Network With Addition of MinuteClinic

PHILADELPHIA, Oct. 14 /PRNewswire/ — It happens just about every weekend in every emergency room. A child is brought in for treatment for a non-emergency illness such as strep throat. Family doctors and pediatricians typically do not have office hours on Saturday night or Sunday so worried parents often obtain treatment at the ER. Until now, seeking treatment in an emergency room may have been their only option. Independence Blue Cross’ (IBC) Personal Choice(R) members now have a new option: retail clinics.

IBC announced today that, beginning this month, MinuteClinic, which operates retail clinics nationwide, is now a participating health care provider within IBC’s PPO network, enhancing access to care for those IBC members who have Personal Choice coverage. In the southeastern Pennsylvania region there are currently 17 MinuteClinic locations and several more locations are expected to open throughout the area within the next year.

“We want to ensure that our members can achieve and maintain the best possible health outcomes,” said Dr. I. Steven Udvarhelyi, Independence Blue Cross chief medical officer. “That means offering the right programs and facilitating access to high-quality, cost-effective care. Our members lead hectic lives and MinuteClinic retail-based health settings can provide a convenient alternative for common health problems when a member is unable to see his or her primary care physician.”

MinuteClinic is conveniently located inside select CVS/pharmacy stores nationwide. Walk-ins are welcome; no appointment is necessary. PPO members will just show their member identification card and pay their usual out of pocket cost for a primary care visit, which offers an immediate savings for members who might have used an ER instead.

A record of each member visit and the type of care provided can be sent to the member’s family doctor. IBC encourages members to continue to use their primary care physician as their first point of care for common health problems and to recognize that retail health clinics are not meant to treat serious illness or emergency situations.

“Making available this new option for treatment of minor conditions is one more way IBC is helping to improve access to quality care, while reducing some health care costs for our group customers and Personal Choice members, given that this care setting is less expensive than emergency or urgent care settings,” said Dr. Udvarhelyi. “Over time we would expect to see a decrease in some ER visits, as our members begin using MinuteClinic for non-emergencies when their doctor’s office is not accessible. This could positively impact health care cost trends,” he added.

“Independence Blue Cross shares our goals of creating consumer-driven health care solutions that provide convenient access and deliver cost savings,” said Chip Phillips, president of MinuteClinic. “By offering quality treatment in a convenient setting, we are working with IBC to help reduce health care expenses for their members as well as time spent away from their families and the workplace.”

MinuteClinic locations are overseen by medical directors and staffed by certified registered nurse practitioners who diagnose, treat, and prescribe medications for certain common family illnesses, such as strep throat, bronchitis, and ear, eye and sinus infections when clinically appropriate. Other examples of health services include treatment for allergies, bladder infections, tick bites, flu, and minor burns. MinuteClinic also offers health screenings, pregnancy testing, vaccinations, and camp physicals.

Open seven days a week, typical hours of operation of MinuteClinic are Monday through Friday, 8 a.m. to 8 p.m., Saturday and Sunday, 10 a.m. to 4 p.m. Supervising physicians are on-call during all clinic hours of operation to provide guidance and direction when necessary.

MinuteClinic provides treatment that follows nationally established clinical practice guidelines from the American Academy of Family Physicians and the American Academy of Pediatrics.

Find participating MinuteClinic locations at http://www.ibx.com/ or through IBC’s member portal at http://www.ibxpress.com/. For locations outside the Personal Choice service area, members can find participating MinuteClinic sites by visiting http://www.bcbs.com/healthtravel/finder.html.

About Independence Blue Cross

Independence Blue Cross is a leading health insurer in southeastern Pennsylvania. IBC and its affiliates provide coverage to nearly 3.4 million people nationwide. For 70 years, Independence Blue Cross has offered high-quality health care coverage tailored to meet the changing needs of members, employers, and health care professionals. Independence Blue Cross is an independent licensee of the Blue Cross Blue Shield Association, an association of independent Blue Cross and Blue Shield Plans. For more information visit http://www.ibx.com/.

About MinuteClinic

Minneapolis-based MinuteClinic is a subsidiary of CVS Caremark Corporation , the largest provider of prescriptions in the nation. MinuteClinic launched the first retail health care centers in the United States in 2000 and is the first provider to establish a national presence with more than 540 locations across the country. The company has generated more than 2 million patient visits, with a 95 percent customer satisfaction rating. MinuteClinic is the first and only retail health care provider to receive accreditation from The Joint Commission, the national evaluation and certifying agency for nearly 15,000 health care organizations and programs in the United States. For more information, visit http://www.minuteclinic.com/.

Independence Blue Cross

CONTACT: Karen Burnham of Independence Blue Cross, +1-215-241-3106,[email protected]

Web site: http://www.ibx.com/http://www.ibxpress.com/http://www.minuteclinic.com/

Gold’s Gym Announces The Top Ten Fittest Presidents of All Time

DALLAS, Oct. 14 /PRNewswire/ — With the 2008 presidential election weeks away, Gold’s Gym, the world’s leading fitness authority, released an analysis of the ten fittest presidents throughout American history, taking a look at the role exercise has played in shaping each presidency. The Gold’s Gym-sponsored research revealed that the fitness routines of the 43 leaders who have occupied the White House were as diverse as their various leadership styles. John Quincy Adams, admired during his day for his Potomac River swims, topped Gold’s Gym’s list as the fittest president of all time.

Research into the fitness routines of the country’s Commanders-in-Chiefs revealed that Adams and nine others were true standouts, and that they maintained an active lifestyle in very different ways. From bowling to canoeing to the “Hoover Ball” — a sport invented to improve the health of the 31st president, these different activities helped make each president “fit to lead.”

Gold’s Gym has ranked the top ten fittest presidents but in true democratic fashion, Americans are also invited to cast their vote in a presidential fitness election at goldsgym.com.

Gold’s Gym — Ten Fittest Presidents of All Time

1. John Quincy Adams — 6th President — Beacon of physical and intellectual fitness

One of the most intelligent and disciplined men to lead the country, Adams kept his body almost as active as his mind with three-to-four mile daily walks and (some say naked) swims in the Potomac

2. George W. Bush — 43rd President — Popularity in the polls might be low, but his body fat percentage is lower

An avid cyclist, Dubya is said to exercise six days a week and steers clear of alcohol and cigarettes

3. Gerald Ford — 38th President — The longest-living ex-president; turned down professional football for a career in law and politics

Ford, who died at age 93 in 2006, may have owed some of his longevity to his athleticism. A former collegiate football star at the University of Michigan, Ford captured MVP honors during his senior year and turned down contracts with the Green Bay Packers and Chicago Bears for a career in law and politics

4. Jimmy Carter — 39th President — Insatiable outdoorsman and author of “An Outdoor Journal”

Since boyhood, Carter has enjoyed physical fitness activities that range from hunting and fishing to mountain climbing and skiing

5. Theodore Roosevelt — 26th President — Advocate of “the strenuous life” — pushing one’s physical limitations

Roosevelt fought through a series of childhood ailments with determination and, as an adult, took up a number of physical activities including boxing, horseback riding and hunting — and even became a cowboy

6. Harry S. Truman — 33rd President — Installed a horseshoe pit and bowling lanes on the White House grounds

When sworn in, Truman appeared as the picture of health. In addition to installing a horseshoe pit and two bowling lanes at the White House, Truman was an avid walker and swimmer

7. Zachary Taylor — 12th President — Known as “Old Rough and Ready” and always ready to throw himself into battle

A regular exercise regimen didn’t always center on jogging and strength training. During Zachary Taylor’s day, military activity was a fundamental way to whip your body into shape and Taylor served in the army for 40 years. Despite his devotion to fitness, Taylor’s time in office was cut short when he died from what may have been cholera

8. Thomas Jefferson — 3rd President — Declaration of Independence author believed “a strong body makes the mind strong”

One “self-evident truth” that Jefferson believed in was that a person should be both physically and mentally fit. The legendary author of the Declaration of Independence enjoyed horseback riding, fishing and taking long walks, the latter of which he thought could be used to clear one’s mind

9. Herbert Hoover — 31st President — Had his own sport, “Hoover Ball”

Once called “notoriously lackadaisical” by the New York Times, Hoover’s physician remedied his sedentary behavior with the invention of a challenging combination of tennis and volleyball that employed a medicine ball and an eight foot tall net. The game was later dubbed “Hoover Ball” — and Hoover stuck to the regimen, playing nearly every morning at 7 a.m. before official White House business began

10. George Washington — 1st President — Before “Dancing with the Stars,” George Washington enjoyed jigs and country dancing

As a boy, the Virginia native kept active by canoeing down the Shenandoah River and, later in life, enjoyed dancing

About Gold’s Gym

Established in Venice, Calif. in 1965, Gold’s Gym is the largest full service gym chain in the world with over 620 locations in 43 states and 30 countries. Gold’s Gym offers the latest equipment and services, including group exercise, personal training, cardiovascular equipment, spinning, Pilates and yoga. With nearly 3 million members worldwide, Gold’s Gym helps all kinds of people achieve their individual potential through fitness.

Gold?s Gym

CONTACT: Shaun Leavy of MWW Group, +1-201-964-2427, [email protected]; orDave Reiseman of Gold’s Gym International, +1-214-296-5062,[email protected]

Web Site: http://www.goldsgym.com/

Insufficient Vitamin D Linked To Parkinsons Disease

A majority of Parkinson’s disease patients had insufficient levels of vitamin D in a new study from Emory University School of Medicine.

The fraction of Parkinson’s patients with vitamin D insufficiency, 55 percent, was significantly more than patients with Alzheimer’s disease (41 percent) or healthy elderly people (36 percent).

The results are published in the October issue of Archives of Neurology.

The finding adds to evidence that low vitamin D is associated with Parkinson’s, says first author Marian Evatt, MD, assistant professor of neurology at Emory.

Evatt is assistant director of the Movement Disorders Program at Wesley Woods Hospital. The senior author is endocrinologist Vin Tangpricha, MD, assistant professor of medicine at Emory and director of the Endocrine Clinical Research Unit.

Evatt says her team compared Parkinson’s patients to Alzheimer’s patients because they wanted to evaluate the possibility that neurodegenerative diseases in general lead to vitamin D insufficiency.

Most Americans get the majority of their vitamin D from exposure to sunlight or by dietary supplements; fortified foods such as milk and packaged cereals are a minor source. Only a few foods in nature contain substantial amounts of vitamin D, such as salmon and tuna.

The body’s ability to produce vitamin D using UV-B radiation from the sun decreases with age, making older individuals at increased risk of vitamin D deficiency.

“We found that vitamin D insufficiency may have a unique association with Parkinson’s, which is intriguing and warrants further investigation,” Evatt says.

The connection could come partly because patients with Parkinson’s have mobility problems and are seldom exposed to the sun, or because low vitamin D levels are in some way related to the genesis or progression of the disease.

She says her team saw their results as striking because their study group came from the Southeast, not a region with long gloomy winters, where vitamin D insufficiency is thought to be more of a problem.

In addition, the study found that the fraction of patients with the lowest levels of vitamin D, described as vitamin D deficiency, was higher (23 percent) in the Parkinson’s group than the Alzheimer’s group (16 percent) or the healthy group (10 percent).

The retrospective study examined 100 people in each group, who were recruited between 1992 and 2007. Every fifth Parkinson’s patient from Emory’s clinical neurology database was selected, then healthy controls and patients with Alzheimer’s disease were matched on age and state of residence.

Vitamin D insufficiency is frequently defined as less than 30 nanograms per milliliter of blood of the 25-hydroxy form (the major storage form) of the vitamin and deficiency as less than 20 nanograms per milliliter. However, most experts agree insufficiency warrants treatment and should not be ignored.

Doctors have known for decades that vitamin D plays a role in bone formation, Evatt says. More recently, scientists have been uncovering its effects elsewhere, including producing peptides that fight microbes in the skin, regulating blood pressure and insulin levels, and maintaining the nervous system. Low vitamin D levels also appear to increase the risk of several cancers and auto-immune diseases such as multiple sclerosis and diabetes.

Parkinson’s disease affects nerve cells in several parts of the brain, particularly those that use the chemical messenger dopamine to control movement. The most common symptoms are tremor, stiffness and slowness of movement. These can be treated with oral replacement of dopamine.

Previous studies have shown that the part of the brain affected most by Parkinson’s, the substantia nigra, has high levels of the vitamin D receptor, which suggests vitamin D may be important for normal functions of these cells, Evatt says.

Emory clinicians are conducting further research to investigate whether vitamin D insufficiency is a cause or possibly a result of having Parkinson’s. In a pilot study, Parkinson’s patients are receiving either standard or larger doses of vitamin D, with an eye towards possibly reducing the severity of their condition.

The research was funded by the National Center for Research Resources, the National Institute of Aging and the National Institute of Environmental Health Sciences of the National Institutes of Health, and by an anonymous donor.

Reference: Evatt M.L et al Prevalence of Vitamin D Insufficiency in Patients with Parkinson Disease and Alzheimer Disease. Arch. Neurol. Vol 65, p. 1348-1352 Oct 2008.

On the Net:

Houston Northwest Medical Center Receives Clinical Excellence Awards for Several Service Lines

HOUSTON, Oct. 14 /PRNewswire-FirstCall/ — Houston Northwest Medical Center today announced that it has received the 2009 Specialty Excellence Awards for Stroke, Critical Care and General Surgery from HealthGrades, a leading independent healthcare ratings company. These awards place Houston Northwest Medical Center’s clinical outcomes in the top ten percent nationally for each recognized area of care.

   Other 2009 notable accolades include:    --  Five-Star Rated for Treatment of Heart Attack and Heart Failure   --  Five-Star Rated for Spinal Fusion Two Years in a Row   --  Five-Star Rated for Treatment of Stroke Three Years in a Row   --  Received the Highest Possible Five-Star Rated for the Treatment of       Pneumonia Two Years in a Row   --  Five-Star Rated for Treatment of Respiratory Failure Four Years in a       Row   --  Received the Highest Possible Star Ratings for Treatment of Sepsis       Three Years in a Row   

“Houston Northwest Medical Center is focused on delivering quality care for our patients. We take great pride in obtaining multiple awards from HealthGrades based on medical outcomes,” said Drew Kahn, FACHE, chief executive officer at Houston Northwest Medical Center. “At Houston Northwest Medical Center, our top priorities are patient safety and clinical quality. Recognition for our quality care is a credit to the outstanding efforts of our physicians, nurses and staff,” added Kahn.

These findings were included in the eleventh annual HealthGrades Hospital Quality in America Study, analyzing more than 41 million Medicare hospitalization records from 2005 to 2007 at the nation’s approximately 5,000 non-federal hospitals.

Based on the study, HealthGrades today made available its 2009 quality ratings for virtually every hospital in the country at http://www.healthgrades.com/, a Web site designed to help individuals research and compare local healthcare providers.

On its Web site, HealthGrades offers, free to consumers, quality ratings of 27 procedures and treatments for virtually every hospital in the country. The Web site is designed so that consumers can easily compare patient outcomes at their local hospitals for procedures ranging from aortic aneurysm repair to bypass surgery. Each hospital receives a star rating based on its patient outcomes in terms of mortality or complication rates for each procedure or treatment. Hospitals with outcomes that are above average to a statistically significant degree receive a five-star rating. Hospitals with average outcomes receive a three-star rating, and hospitals with outcomes that are below average receive a one-star rating. Because no two hospitals or their patients’ risk profiles are alike, HealthGrades employs extensive risk-adjustment algorithms to ensure that it is making analogous comparisons.

About Houston Northwest Medical Center

Houston Northwest Medical Center is located at 710 F.M. 1960 West in Houston. Houston Northwest Medical Center has been serving the North Houston community for 35 years. The hospital is an Accredited Chest Pain Center by the Society of Chest Pain Centers. Houston Northwest Medical Center ranks among the nation’s top hospitals for several service lines from HealthGrades, a leading source for independent health care quality information, including overall gastrointestinal services, gastrointestinal surgery, stroke, general surgery, maternity care, back and neck surgery (spinal fusion), overall critical care services, and overall pulmonary services. Houston Northwest Medical Center is also a Blue Cross/Blue Shield Center for excellence in weight loss surgery. To learn more about Houston Northwest Medical Center, a facility accredited by the Joint Commission on Accreditation of Healthcare Organizations, visit http://www.hnmc.com/.

   Contact: Theresa Lewis   Marketing Manager   Houston Northwest Medical Center   (281) 440-2444   [email protected]     HealthGrades Contact:   Scott Shapiro   Senior Vice President, Corporate Communications   (720) 963-6584   [email protected]  

Houston Northwest Medical Center

CONTACT: Theresa Lewis, Marketing Manager of Houston Northwest MedicalCenter, +1-281-440-2444, [email protected]; or Scott Shapiro,Senior Vice President, Corporate Communications of HealthGrades,+1-720-963-6584, [email protected]

Web Site: http://www.healthgrades.com/http://www.hnmc.com/

Abraxis BioScience Names Edward Geehr, M.D., Executive Vice President of Operations

Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated, global biotechnology company, today announced that Edward C. Geehr, M.D., has joined the company as Executive Vice President of Operations. Dr. Geehr, 59, will report to Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer of Abraxis BioScience.

In this newly created position, Dr. Geehr will be responsible for the commercial, manufacturing and marketing operations of Abraxis. “Edward Geehr’s extensive operational knowledge gained from serving in key management roles, and his experience guiding companies during periods of rapid growth, will support the expansion of Abraxis as we continue to broaden the company’s commercial operations,” said Patrick Soon-Shiong, M.D., Chairman and Chief Executive Officer of Abraxis BioScience. “Ed’s career combines both entrepreneurial and executive experience in the healthcare industry, an important foundation that will serve Abraxis BioScience. Ed is a welcome addition to our management team as we continue to launch ABRAXANE(R) in countries around the world, enhance our robust clinical program and invest in drug discovery both internally and through industry and academic partnerships.”

Dr. Geehr has extensive experience as a founder, manager and board member of companies in the fields of medical devices, health services and technology. His responsibilities have included business planning, finance, hiring of management teams, product development, regulatory compliance, and national marketing, sales, and distribution. Most recently, Dr. Geehr has been serving as president of Allez Spine LLC, an Irvine, California-based medical device company. He has also served as founding chairman and chief medical officer of IPC – The Hospitalist Company, now a publicly-traded North Hollywood, California-based medical services company that organizes and manages hospital-based medical practices in multiple states. Prior to IPC, Dr. Geehr was Senior Vice President of UniHealth America, an integrated healthcare delivery and insurance system based in Burbank, California with multi-specialty medical groups, multiple hospital operations and holdings in health insurance plans.

Dr. Geehr also was associate clinical professor of medicine and surgery at the University of California, San Francisco, and chief of emergency medicine at San Francisco General Hospital. Additionally, he was professor and chairman of emergency medicine and general director of hospital operations at Albany Medical College. He received his B.A. from Yale University and M.D. from Duke University with a residency in emergency medicine at the University of California, Los Angeles.

Dr. Geehr serves as a member of the board of directors of MedManage Systems, an online pharmaceutical samples company based in Bothell, Washington, and LifeScript, an online health information company based in Mission Viejo, California.

About Abraxis BioScience

Abraxis BioScience is a fully integrated global biotechnology company dedicated to the discovery, development and delivery of next-generation therapeutics and core technologies that offer patients safer and more effective treatments for cancer and other critical illnesses. The company’s portfolio includes the world’s first and only protein-bound chemotherapeutic compound (ABRAXANE), which is based on the company’s proprietary tumor targeting technology known as the nab(TM) platform. The first FDA approved product to use this nab(TM) platform, ABRAXANE, was launched in 2005 for the treatment of metastatic breast cancer. Abraxis trades on the NASDAQ Global Market under the symbol ABII. For more information about the company and its products, please visit www.abraxisbio.com.

Introducing Palmaz Scientific, Inc.

Julio Palmaz, M.D. made his mark on the medical world 20 years ago with the invention of the stent which revolutionized cardiac care, and now more than a million people each year undergo coronary artery stenting to repair clogged arteries. Today, Dr. Palmaz leads a team of scientists and high tech engineers at newly established Palmaz Scientific, Inc. on a mission to create safer and more predictable implantable prosthetic devices. Dr. Palmaz and his colleagues will introduce Palmaz Scientific, a new operating business, and present clinical trial results of the company’s first application of its innovative technologies at a satellite meeting of the Transcatheter Cardiovascular Therapeutics Conference in Washington, D.C. today.

“The use of stents and other implantable devices in treating cardiac and other diseases has saved lives and advanced medical intervention,” said Dr. Palmaz, chairman, co-founder and chief scientist of Palmaz Scientific, Inc. “However, inherent to all coronary implantables currently on the market are the risks of restenosis, stent thrombosis, embolization and the need of antiplatelet medications. By re-engineering the surface of the implants to better accommodate tissue and blood interactions and utilizing high technology processes yielding high purity materials in our all-metal micromesh stents, Palmaz Scientific plans to introduce a new class of stents and other implantable devices for a number of medical applications,” he added.

For the past ten years, Dr. Palmaz and his team have researched the biochemical and molecular changes that occur with implants. They discovered that the type of materials used as well as their surface chemistry and configuration play a major role in the body’s response to the implant and attendant complications resulting from inadequate healing at the implant site. The Palmaz team developed the technology to manufacture stents, balloons and other devices using physical vapor deposition processing techniques — similar to those used in microelectronics manufacturing — to create an all metal, nitinol micromesh covered stent to promote endothelialization. The company has conducted extensive laboratory and preliminary clinical research on its proprietary thin film technology products and currently holds 37 U.S. and foreign patents related to the technology and property, with an additional 157 currently pending.

Steven B. Solomon, co-founder, director and chief executive officer of Palmaz Scientific, said, “The research done thus far indicates that this thin film technology will improve the patient’s healing rate and outcome. This not only makes for improved overall results, but reduces the need for repeat procedures and reassures physicians about long term benefits. Our first anticipated market opportunity for this technology will be the SESAME stent for use in coronary artery bypass grafts,” he added. “We expect to launch this product in Europe in 2009 and to initiate a larger-scale clinical trial with SESAME in the U.S. soon.”

In addition to coronary artery and cardiac applications, Palmaz Scientific expects to develop products for use in renal, carotid, peripheral (upper and lower extremities) as well as non-vascular prosthetics for orthopedic and plastic and reconstructive surgeries.

About Palmaz Scientific, Inc. (www.palmazscientific.com)

Palmaz Scientific has innovated a new platform for implantable prosthetic devices and is armed with an extensive intellectual property portfolio of patented and patent pending thin film metal surface technologies and processing methods. The Company holds 37 patents issued in the United States and internationally, as well as 157 patent applications pending on its technologies including the thin film physical vapor deposition technologies for use in medical implantable devices. With this unique technology, the company believes that it is the first and only company positioned to develop and manufacture a new generation of all metal micromesh covered stents for the cardiovascular market, while also developing other implantable prosthetic devices for the orthopedic and cosmetic implant markets, to fulfill its mission of creating safer and more predictable implantable prosthetic devices for a variety of medical needs. The Company is headquartered in Dallas, Texas and has operations in Fremont, California.

 For additional information contact:  Steve Solomon CEO Phone:  214-520-9292 Email: Email Contact  Susan Rogers Alchemy Consulting, Inc. Phone:  650-430-3777 Email: Email Contact

SOURCE: Palmaz Scientific, Inc.

Neurogen Announces Positive Results for Aplindore in Restless Legs Syndrome and Parkinson’s Disease

Neurogen Corporation (Nasdaq: NRGN) today announced positive top-line results from two Phase 2 clinical trials in restless legs syndrome (RLS) and Parkinson’s disease with the Company’s dopamine partial agonist, aplindore. These studies were the first in which aplindore has been evaluated in RLS and Parkinson’s disease.

In each study, aplindore demonstrated highly significant efficacy and was well tolerated. Neurogen believes aplindore’s dopamine partial agonist controlled release profile may be better tolerated, with fewer side effects and greater dosing flexibility, than existing drugs to treat RLS and Parkinson’s disease. Side effects of RLS drugs currently on the market or in late-stage development include daytime somnolence, dizziness and nausea. These drugs require titration, or slow escalation of doses, over several days or weeks to achieve an effective dose. Side effects of drugs currently available for the treatment of Parkinson’s disease include nausea, somnolence, hallucinations and dyskinesias, or involuntary movements, and also require titration to reach therapeutic doses.

Stephen R. Davis, Neurogen’s President and CEO, said, “In the RLS study, where all subjects received the same 0.05 mg dose on the first day of dosing, we observed statistically significant efficacy at that starting dose. This opens the possibility of dosing aplindore in RLS without prior titration. The potential to provide relief to RLS patients without titration could provide important additional flexibility to physicians and patients. We will further examine this possibility in future studies.”

Mr. Davis continued, “Our objective in the Parkinson’s study was to explore the safety and tolerability of aplindore across various titration schedules and dose ranges in separate groups of patients. We were very pleased not only to successfully achieve this key objective but, in addition, to observe a strong and consistent efficacy response further informing our view of doses to take into the next study.”

Restless legs syndrome

The RLS study was a placebo-controlled, single-blind, multi-center study designed to assess the efficacy, safety and tolerability of single doses of aplindore compared to placebo. The primary efficacy endpoint was the mean change in the Periodic Limb Movement Index (PLMI) during sleep from baseline (placebo treatment night) to the highest achieved aplindore dose. In this study, aplindore achieved statistically significant results versus placebo (see table below) at all doses tested. In addition, aplindore was well tolerated with an incidence of adverse events similar to placebo in doses up to 0.2 mg.

The study enrolled 27 RLS patients, with 26 patients receiving at least one aplindore treatment. In this in-patient study, each subject spent an adaptation night in the sleep laboratory followed by a placebo-dosed (baseline) night and then individual nights of sequentially increasing doses of aplindore from 0.05 mg to 0.2 mg. If a subject demonstrated less than a 50% reduction in PLMI from baseline at the 0.2 mg dose, the dose was escalated to a maximum of 0.7 mg. As planned, an interim analysis on the primary efficacy endpoint was conducted when a sufficient number of evaluable patients was reached (n=19). Results of this interim analysis indicated a significant reduction (p less than 0.0001) in the mean PLMI at a level higher than the pre-specified criterion (alpha=0.01) for stopping the study. On the basis of these results, the study was terminated following the interim analysis. The same outcomes and conclusion were also reached when a sensitivity analysis was performed including all patients treated with aplindore (n=26).

The following table shows mean PLMI for each dose group:

 Periodic Limb Movement Index (PLMI) During Sleep ---------------------------------------------------------------------- aplindore aplindore aplindore aplindore placebo  0.05 mg   0.1 mg    0.2 mg    highest dose ---------------------------------------------------------------------- Mean PLMI    33.97    13.88     9.12      8.24      8.20 PRIMARY        ------------------------------------------------------- ANALYSIS       Mean (EVALUABLE)     Change POPULATION      from (n=19)          Placebo         -16.66    -24.85    -23.95    -25.77 ------------------------------------------------------- p-value                   less than           less than 0.0159     0.0001   0.0002     0.0001 ---------------------------------------------------------------------- Mean PLMI    35.82    16.53     14.46     13.04     12.83 ------------------------------------------------------- ALL            Mean APLINDORE       Change PATIENTS        from (n=26)          Placebo         -16.89    -21.61    -20.07    -22.98 ------------------------------------------------------- p-value                             less than 0.0035    0.0003     0.0001   0.0001 ---------------------------------------------------------------------- 

Parkinson’s disease

The Parkinson’s study was a dose-ranging, randomized, double-blind, placebo-controlled, parallel design exploratory study of the safety, tolerability, efficacy and pharmacokinetics of aplindore in patients with early stage Parkinson’s disease. The primary objective was to evaluate in five separate groups of patients the safety and tolerability of aplindore given BID over two weeks in varying titration schedules and across different dose ranges. Additionally, the study was designed to generate efficacy data with aplindore compared to placebo as measured by the mean change in the Unified Parkinson’s Disease Rating Scale (UPDRS) Motor Score (Part III). Aplindore achieved statistically significant results versus placebo in each of the three lowest dose regimens tested. In addition, aplindore was generally well tolerated and there were no withdrawals due to adverse events and no serious adverse events.

The study enrolled 39 patients, aged 37 to 77 years. Patients were assigned to one of five cohorts, each cohort with a different dose escalation schedule and maximum dose. In each cohort, 5-6 patients were randomized to aplindore and 2 to placebo. Following two weeks of titration to five different maximum daily doses, clinically and statistically significant improvement was observed in the Motor Score (Part III) of the UPDRS in the cohorts dosed at 2 mg BID, 3 mg BID and 5 mg BID of aplindore compared to placebo-treated patients. Patients titrated to higher aplindore doses (9 mg BID and 15 mg BID) over the same two-week period of time showed improvements that did not separate statistically from placebo. This finding suggests a possible decrease or plateauing of the observed effect in the upper dose range and that the future evaluation of aplindore should focus on the lower dose ranges.

The following table shows mean change from baseline in UPDRS, Part III (Motor) Score:

 Unified Parkinson Disease Rating Scale, Part III (Motor) Score (2 hours post-dose) ---------------------------------------------------------------------- MAXIMUM ACHIEVED DOSE OF APLINDORE  POOLED       (two weeks dose escalating treatment) PLACEBO   --------------------------------------------- (n=10)   2 mg BID 3 mg BID 5 mg BID 9 mg BID 15 mg BID (n=5)    (n=6)    (n=6)    (n=6)     (n=6) ---------------------------------------------------------------------- Mean Change From Baseline   -3.3     -10.8    -12.3    -10.2     -4.8     -5.3 ---------------------------------------------------------------------- p-value                0.0243   0.0026   0.0107     ns       ns ---------------------------------------------------------------------- 

Webcast

Neurogen will host a conference call and webcast to discuss this announcement at 8:30 ET today. The webcast will be available in the Investor Relations section of www.neurogen.com and will also be archived there. A replay of the call will be available after 10:30 am ET today and accessible through the close of business, October 21, 2008. To replay the conference call, dial 888-286-8010, or for international callers, 617-801-6888, and use the pass code: 56098936.

About Neurogen

Neurogen Corporation is a drug development company focusing on small-molecule drugs to improve the lives of patients suffering from disorders with significant unmet medical need, including restless legs syndrome (RLS), Parkinson’s disease, insomnia, anxiety and pain. Neurogen conducts its drug development independently and, when advantageous, collaborates with world-class pharmaceutical companies to access additional resources and expertise.

Safe Harbor Statement

The information in this press release contains certain forward-looking statements, made pursuant to applicable securities laws that involve risks and uncertainties as detailed from time to time in Neurogen’s SEC filings, including its most recent 10-K. Such forward-looking statements relate to events or developments that we expect or anticipate will occur in the future and include, but are not limited to, statements that are not historical facts relating to the timing and occurrence of anticipated clinical trials, and potential collaborations or extensions of existing collaborations. Actual results may differ materially from such forward-looking statements as a result of various factors, including, but not limited to, risks associated with the inherent uncertainty of drug research and development, difficulties or delays in development, testing, regulatory approval, production and marketing of any of the Company’s drug candidates, adverse side effects or inadequate therapeutic efficacy or pharmacokinetic properties of the Company’s drug candidates or other properties of drug candidates which could make them unattractive for commercialization, advancement of competitive products, dependence on corporate partners, the Company’s ability to retain key employees, sufficiency of cash to fund the Company’s planned operations and patent, product liability and third party reimbursement risks associated with the pharmaceutical industry. For such statements, Neurogen claims the protection of applicable laws. Future results may also differ from previously reported results. For example, positive results or safety and tolerability in one clinical study provide no assurance that this will be true in future studies. Neurogen disclaims any intent and does not assume any obligation to update these forward-looking statements, other than as may be required under applicable law.

Ikonisys Reports Positive Results From Clinical Study Designed to Evaluate the Efficacy of Circulating Tumor Cell Detection With Ikonisys’ Automated Microscope

Ikonisys, a leading provider of next-generation, cell-based diagnostic solutions, today announced positive results from a clinical study conducted by a research group at the Weatherall Institute of Molecular Medicine at Oxford University, a laboratory supported by Cancer Research U.K. (CRUK), the country’s leading cancer charity. The study validates the company’s CellOptics(R) platform and proprietary digital microscope, the Ikoniscope(R), as a viable method for quickly and easily detecting and detailing circulating tumor cells (CTC) in the blood. The findings, published in the British Journal of Cancer (September 2008), represent a significant milestone for screening and disease monitoring for a variety of cancers, including prostate, colorectal and ovarian.

Led by world-renowned scientist, Sir Walter Bodmer, the study demonstrates the importance of CTC detection in providing a new and effective approach to the overall management of cancer. The study analyzed blood samples from several patients with prostate, colorectal and ovarian cancer. The blood samples were analyzed using the Ikoniscope, a fully-automated, fluorescence microscopy imaging system. CTCs were detected in 23 of 25 colorectal, 10 of 10 prostate and four of four ovarian cancer patients. Overall, study results show that CTCs could be used for early cancer screening, detection of recurrence and evaluation of response to therapy.

“I am very excited about the possibilities of this technology both for monitoring cancer recurrence and for screening for selected cancers,” said lead author Sir Walter Bodmer, director of the Cancer and Immunogenetics Laboratory, Weatherall Institute of Molecular Medicine, Oxford University. “The application could be particularly valuable in preventing an excess of false positives in PSA testing.”

“We are very pleased with the results of the study and the impact they have on our goal of improving current screening methods for cancer detection,” said Dr. Petros Tsipouras, Ikonisys CEO and chairman. “Given the recent recommendation to stop routine prostate cancer screening in men aged 75 and older, the results are especially exciting as they suggest this method may be an effective way to increase the number of positive biopsies based on elevated PSA levels. This new method of detecting CTCs shows great promise in our continuous quest to provide physicians and patients with early, accurate screening methods that ultimately enable personalized medical treatments.”

Through its breakthrough CellOptics platform, Ikonisys is developing a stream of proprietary and non-proprietary tests based on the detection of rare cells in a practical, efficient and economical manner. At the center of the platform is the Ikoniscope, a robotic, high-throughput, image acquisition and display microscopy system that is used for rare cell detection and analysis in an entirely digital environment, helping lab technicians to find the few cells out of millions that matter. In addition to simply presenting cell images to the lab technician, the platform analyzes the cells, offering an interpretation of the progression, while simultaneously allowing the pathologist to concur or override the analysis. This intelligent technology is ultimately laying the groundwork for a “virtual digital assistant” to the pathologist.

About Ikonisys

Ikonisys is changing the practice of diagnostic medicine through its unique CellOptics platform – an innovative combination of intelligent imaging, microscopy, biology and informatics – that enables Ikonisys to deliver diagnostic test solutions that are automated, innovative and integrated. By providing “walk away” automation solutions, Ikonisys enables reference labs, hospitals, research institutions and practice groups to both greatly expand their test volume capacity and standardize their diagnostic procedures. This will further enhance their ability to economically deliver accurate, fast and personalized results for early cancer diagnosis and monitoring, and genetic disorder screening to physicians and researchers.

In addition to automating existing FISH-based tests, the CellOptics platform enables Ikonisys to launch a stream of next-generation diagnostic tests that are based on the detection of rare cells in a practical, efficient and economical manner. These “signature” tests will include proprietary test specific reagents. The integration capabilities of the CellOptics platform provides for both the transfer of patient test data into a laboratory’s information systems – enabling the creation of more comprehensive patient medical records – as well as the potential to utilize these novel tests as companion diagnostics, which provides a path to fully realize the promise of personalized medicine.

In 2006, Ikonisys obtained FDA clearance for fastFISH(R) amnio, an imaging application for the Ikoniscope that provides automated identification of numerical aberrations of chromosomes associated with common birth defects. Additionally, in early 2007, the company received FDA clearance for oncoFISH(R) bladder, an Ikoniscope application that helps in the initial diagnosis of bladder cancer.

About the British Journal of Cancer

The BJC is owned by Cancer Research UK. Its mission is to encourage communication of the very best cancer research from laboratories and clinics in all countries. Broad coverage, its editorial independence and consistent high standards have made BJC one of the world’s premier general cancer journals. www.bjcancer.com.

American Council on Exercise (ACE) Studies Impact of Boot Camp-Style Workouts

SAN DIEGO, Oct. 14 /PRNewswire/ — The American Council on Exercise (ACE), America’s leading authority on fitness and one of the largest fitness certification, education and training organizations in the world, today announced key findings from an exclusive study conducted at the University of Wisconsin, La Crosse through its exercise and health program on the benefits of boot camp workouts. Results concluded that a typical boot camp-style workout will enhance aerobic capacity and promote significant calorie burning while also improving muscle fitness.

“From a cardiovascular and calorie-burning standpoint, the boot camp-style workout evaluated in this study compared favorably to traditional aerobic activities like group cycling, aerobic dancing, and cardio-kickboxing,” says ACE’s Chief Science Officer Cedric X. Bryant, Ph.D. “During a boot camp workout, you can burn up to 600 calories per hour, which is obviously going to help with weight loss. But in addition to a great cardiovascular workout, you are also getting the muscular fitness benefit from exercises such as pushups, squats and lunges that you wouldn’t get from a typical aerobic exercise.”

The study tested men and women between the ages of 19-29 years old and was led by John Porcari, Ph.D.; Karel Schmidt, B.S.; and Kirsten Hendrickson, a graduate student in exercise and sports science at the University of Wisconsin, La Crosse. Researchers used a 40-minute video to measure the effects of boot camp-style workouts called The Method: Cardio Boot Camp with Tracy Mallett, which incorporated a balance of aerobic exercise and strength training.

The study concluded the average exerciser burns approximately 9.8 calories per minute during a typical boot camp-style work out. This equates to about 400 calories during a 40-minute video or 600 calories per hour. While boot camp classes offer a more total-body workout than running on a treadmill, ACE recommends a well-balanced fitness program for best results. Look for classes or videos that incorporate both aerobic movements and calisthenics.

Based upon the data collected in this study, subjects were exercising well within industry-accepted guidelines for exercise intensity. Study participants were observed to achieve an exercise heart rate that ranged from approximately 70 to 90% of maximum heart rate and 60 to 80% of maximum oxygen uptake which corresponds to a moderate- to high-intensity level of exercise.

“Overall, boot camp is a great total-body workout because it provides interval training that incorporates both high-intensity and low-intensity moves,” Bryant continues. “It is a great option for anyone looking for a fun, motivating workout that offers variety, provides some strength training and, effectively burns calories.”

A complete study summary appears in the July/August 2008 edition of ACE Fitness Matters magazine or on the ACE Web site at http://www.acefitness.org/cp/pdfs/FitnessMatters/Sept08.pdf

About ACE

The American Council on Exercise (ACE), America’s premier certification, education and training organization, is a nonprofit organization dedicated to promoting the benefits of physical activity and protecting consumers against unsafe and ineffective fitness products and instruction. ACE sponsors university-based exercise science research and is the world’s largest nonprofit fitness certifying organization. For more information on ACE and its programs, call (800) 825-3636 or log onto the ACE Web site at http://www.acefitness.org/.

The American Council on Exercise

CONTACT: Tara Shaffer of Formula, +1-619-234-0345,[email protected], for The American Council on Exercise

Web site: http://www.acefitness.org/

Go Healthy Receives Testimonial From Joe Ninowski, Jr., Music Director of Daystar Television

SPRING, Texas, Oct. 14 /PRNewswire-FirstCall/ — Go Healthy, Inc. (Pink Sheets: GOHE) announced today that the company has received a letter of appreciation and endorsement regarding the value of the Go Healthy products from Joe Ninowski, Jr., Music Director of Daystar Television Network.

Joe stated, “One of life’s greatest gifts is Good Health! With our busy schedules and daily challenges our health can suffer, especially in the area of nutrition. That is why I absolutely love the Go Healthy products (shakes, bars and Cholesterade(R)) because they provide convenient, state-of-the-art nutrition that can keep you healthy AND make you healthier!” The letter also stated, “… The ability to have scientifically proven sustenance that tastes phenomenal … anywhere, anytime … and that I can recommend to family (my kids and wife love the stuff!), friends and colleagues … that’s huge.”

Stuart Evey, Chairman of Go Healthy and formerly the founding Chairman of ESPN, states, “This is yet another positive affirmation by Joe Ninowski, Jr. of Daystar that our church outreach program is working. We are excited that our program to get the products into the entire church market is moving forward with great success. As the leaders start using, enjoying and recommending the products, the market has the opportunity to grow rapidly.”

Charlie Caudle, CEO of Go Healthy states, “This is another testimonial that our products taste great and are easy and convenient to use. George Hutson, head of our Government and Religious programs, has done an excellent job of getting recognition of the value of the products by prominent leadership at major church entities, both broadcast and major church groups. Go Healthy is excited to work with these organizations to continue to take our message and our products to the consumer.”

About Go Healthy, Inc.

Go Healthy is an innovative nutritional supplement corporation founded on the great tasting products created by the late Dr. J. Robert Cade, the inventor of Gatorade(R). These natural products are at the core of the cholesterol solution, general nutrition, and energy and muscle recovery. Cholesterade(R) and the Go!(R) Energy Recovery Shakes and Bars are widely recommended by experts in the medical community and selected by major university and pro athletic departments.

Forward-Looking Statements Disclosure

This press release may contain “forward-looking statements” within the meaning of the federal securities laws. In this context, forward-looking statements may address the Company’s expected future business and financial performance, and often contain words such as “anticipates,””believes,””estimates,””expects,””intends,””plans,””seeks,””will,” and other terms with similar meaning. These forward-looking statements by their nature address matters that are, to different degrees, uncertain. Although the Company believes that the assumptions upon which its forward-looking statements are based are reasonable, it can provide no assurances that these assumptions will prove to be correct. All forward-looking statements in this press release are expressly qualified by such cautionary statements, risks, and uncertainties, and by reference to the underlying assumptions.

    Contact:     Charlie Caudle    CEO - Go Healthy, Inc.    (888) 282-7256     Brokers and Analysts call    Aero Financial, Inc    972-265-7590  

Go Healthy, Inc.

CONTACT: Charlie Caudle, CEO of Go Healthy, Inc., 1-888-282-7256; orBrokers and Analysts, Aero Financial, Inc, +1-972-265-7590, for Go Healthy,Inc.

Web site: http://www.go-energy-recovery.com/

Lgh To Issue Standardized Color Wristbands ; Hospital Here Joining National Trend Aimed At Avoiding Confusion, Eliminating Errors.

By Cindy Stauffer

No more wearing purple survivor wristbands or pink breast cancer wristbands or green Darfur wristbands or any other color bands while you’re a patient at Lancaster General Hospital.

Starting next week, the hospital has its own color wristbands, and each has its own special meaning.

Wearing a purple hospital wristband? That means you have a “do not resuscitate” order, directing doctors not to perform cardiopulmonary resuscitation if your heart or breathing stops.

A green wristband means you are allergic to latex. A pink one means you have a restriction on an arm, and it should not be used for drawing blood, taking blood pressure or other procedures.

The new bands are part of a statewide and national trend to standardize the color of wristbands at hospitals, to avoid confusion and medical errors.

Doctors and nurses sometimes work at more than one hospital. Also, patients sometimes are transferred from one hospital to another. Both situations can lead to potentially fatal problems when one color means different things at different hospitals.

That is what happened in 2005 at a Pennsylvania hospital, when a nurse placed a yellow wristband on a patient, thinking it meant a limb restriction. However, at the hospital where the nurse was working that day, a yellow band meant do not resuscitate.

The patient had a heart attack, but fortunately another nurse recognized the error, and the patient was resuscitated.

The mix-up captured the attention of hospital officials across the state and country.

In Pennsylvania, 11 hospitals formed a task force, which ultimately picked five colors and designated them to mean five conditions, falling in line with colors adopted by hospitals across the country.

Both the Hospital & Healthsystem Association of Pennsylvania and the American Hospital Association recently recommended hospitals adopt the system. Across the country, hospitals in Texas, Minnesota and Alabama are following suit, among others.

“It’s just so simple that it makes sense,” says Lisa Brosey, senior director for patient safety and quality at Lancaster General.

Not every hospital is adopting every color, which includes yellow for fall risk and red for allergy. The goal of the system is not to mandate that hospitals adopt colored wristbands. Rather, it is to ensure that, if hospitals use them, the colors are standardized across the state.

Some hospitals here are retaining their own in-house colors while they study the issue.

Lancaster Regional Medical Center and Heart of Lancaster Regional Medical Center use the standardized yellow and red, but use their own system’s color, blue, for do not resuscitate, said Deborah Willwerth, chief operating officer.

Ephrata Community Hospital is studying the issue, spokeswoman Joanne Eshelman said.

“We’re weighing the risks and benefits of the system,” she said.

Lancaster General decided to adopt three of the five colors. It designates fall risks and allergies in a different way, such as by special slippers or by a computerized medication system.

“We didn’t want to have a patient with five armbands,” said Norma Ferdinand, senior vice president and chief quality and nursing officer.

With its new policy, Lancaster General will remove any colored wristbands from other facilities when patients are admitted. It will also ask patients to remove or cover rubber social advocacy wristbands, such as the yellow Livestrong bands.

The designation of each color, such as arm restriction or latex allergy, also appears in writing on the wristband.

Other hospitals in the region that are implementing the standardized program include Hershey Medical Center, PinnacleHealth in Harrisburg and Holy Spirit Hospital in Camp Hill.

(c) 2008 Intelligencer Journal. Provided by ProQuest LLC. All rights Reserved.

Center Provides Alternate Viewpoint

By Shanna Flowers [email protected] 981-3220

A dark mahogany, butter-soft leather sofa beckons visitors into the homey room just inside the door of Roanoke’s Blue Ridge Women’s Center.

A throw blanket is casually draped across the back of the sofa; it’s the same color as the cranberry red pillows perched on nearby leather upholstered chairs. The warm mocha walls are bathed in soft lamp lighting, and a television perched overhead is barely audible.

The sitting room at the Christian-based, anti-abortion women’s center on Williamson Road is comfortable, cozy and welcoming.

The room at the Blue Ridge center is a different side of a movement often typified by attention-seeking protesters outside abortion clinics or in human chains along busy roads.

Two weeks ago, I visited the Blue Ridge center after one of its volunteers called me. She had taken issue with my characterization of social conservatives as lacking compassion for teen mothers.

She noted that several women’s centers, including Blue Ridge, treat unwed pregnant teens with kindness and concern.

So I met with Phil Holsinger, the center’s president and chief executive, as well as staff counselor Susie Amos and director of clinical services Brooke McGlothlin.

I wasn’t prepared to immediately warm to Holsinger and his staff.

But I did, and I developed a new respect for at least a portion of a movement I had thought of as one-dimensional.

Holsinger acknowledged there are some in the anti-abortion cause who are more aggressive in their efforts. But many are not, he added.

“Unfortunately, the rhetoric in our country is always argued from the extremes,” Holsinger said. “We’ve chosen to be the compassionate voice in the midst.”

Caring about mom, too

Established in 1984 as the Crisis Pregnancy Center of Roanoke, Blue Ridge provides free pregnancy testing and counseling to women of varying ages who are pregnant or think they might be. The center, which also has an office in Rocky Mount, also has free maternity clothes and baby items, such as strollers.

Its mission extends beyond getting the baby here but also helping the mother get on her feet.

The center serves about 400 women a year. During its 24 years, it has encountered 858 women who came through the doors considering abortion, but chose to have their babies instead, according to one of its brochures.

Clients include the unmarried and the married, McGlothlin said, and some men accompany their wives or girlfriends. Most of the women are between 18 and 24, but the clinic has seen 13-year-old girls and 50-year-old women.

McGlothlin said many women take over-the-counter pregnancy tests at home but seek a more reliable, laboratory-quality urine test at the clinic.

“More than that, they need someone to help them think through the situation, need someone outside the situation,” she said.

“We convey to the client that this is a safe place,” Amos said. “When the girls come in here, they have a high stress level. We just listen to them.”

Offering hope

Elizabeth Wagner showed up at the center about five months ago, single, pregnant and unemployed. The 21-year-old and her baby’s father were on rocky terms. She was afraid to tell her mother and fearful that her church would reject her.

She wanted her child, but in the swirl of confusion and stress, the option of abortion crossed her mind.

“I needed the confirmation,” Wagner said. “Susie sat down and talked to me and gave me hope.”

Today, Wagner has a job, and she and her mother get along fine. A recent sonogram shows her baby is a girl, and she’s thinking of names.

“I know it’s going to be tough and it’s going to be hard, but God has given me this baby for a reason, and I’m going to take it one step at a time,” she said.

A ministry

Like many others, Wagner learned about the center through word of mouth. Most of them know it is a Christian-based facility.

So they usually are not surprised if a counselor brings up their faith and asks them to speak about it as it relates to their situation, McGlothlin said.

She said counselors ask clients questions such as, “What do you think God thinks about this life you’re carrying? … Do you feel like God has an opinion? Does that matter to you?”

Amos noted that if someone doesn’t want to inject religion into the conversation, “we are not in their face with that.”

At the beginning, the staff informs women that it does not refer for abortions or perform abortions, McGlothlin said. Still, some women who have no intention of carrying their babies to term still visit, she said.

Some merely want to confirm their pregnancy. Others seek information about life skills classes the center offers to help them get their lives on track.

A summer/fall list of classes included childbirth, resume- writing and career counseling, budgeting and abortion recovery. The recovery class is for women who terminated a pregnancy months and even years ago and are struggling with the decision.

“There is no circumstance where we’d say, ‘You are not welcome here.’ We want to be a service to any woman who needs our help,” McGlothlin said.

A call for more workers

The center, has eight full- and part-time workers, and has an annual budget of $365,000. Individual donations make up 71 percent of the budget. Churches give 17 percent and businesses 12 percent.

Overseeing the operation is Holsinger, an ordained minister, former pastor, husband and father. He joined the center in February. Holsinger, who grew up in my hometown of Flint, Mich., is easygoing, engaging and not judgmental. He was not exactly what I expected of the CEO of an anti-abortion center.

Holsinger, 55, used to support abortion rights. Before he met his wife, Cindy, a previous girlfriend became pregnant. The young woman decided to have an abortion, and Holsinger backed her decision.

He said he became a Christian in 1984 and became “pro-life in my mind, not pro-life in my heart.”

His moment of full transformation came six years later. During recovery from testicular cancer, his doctor had told him Cindy should not get pregnant for at least 18 months because of the radiation treatment.

Holsinger had never told his wife about the doctor’s caution.

But one morning in 1990 as he shaved, his wife waved a home pregnancy test in his face.

“God was telling me at that moment that I needed to trust him,” Holsinger said.

He relied on his faith, and eight months later a child arrived, Taylor, who is now a spirited and healthy teenage girl. Holsinger didn’t tell his wife of the doctor’s warning until after their daughter was born.

“I made a decision I was going to trust in God’s goodness.”

Today, Holsinger wants to get a new generation of workers, including more minorities, active in the anti-abortion cause.

“The problem we have in pregnancy ministry work is too much gray hair,” he said before 500 supporters at the center’s annual banquet Oct. 2. “The next generation has to be equipped to be ready to serve.”

(c) 2008 Roanoke Times & World News. Provided by ProQuest LLC. All rights Reserved.